0001663038false--07-31FY2025false7500000000.00001389620503477705013000000010000000100000000.000010.000010.00001000500000500500falsefalsefalsefalse00016630382024-08-012025-07-310001663038us-gaap:SeriesAPreferredStockMember2024-08-012025-07-310001663038us-gaap:SeriesBPreferredStockMember2024-08-012025-07-3100016630382023-03-012023-03-3100016630382023-02-210001663038relia:TopMember2023-02-210001663038relia:BottomMember2023-02-2100016630382023-07-012023-07-1700016630382023-07-012023-07-2500016630382024-09-012024-09-1200016630382021-06-012021-06-140001663038relia:JulyThirtyOneTwoThousandTwentyFiveMember2024-07-310001663038relia:AprilThirtyTwoThousandTwentyFiveMember2024-07-310001663038relia:MarchFourTwoThousandTwentyFiveMember2024-07-310001663038relia:AugustSixteenTwoThousandTwentyFourMember2024-07-310001663038relia:FebruaryElevenTwoThousandTwentyFiveMember2024-07-310001663038relia:DecemberSevenTwoThousandTwentyFourMember2024-07-310001663038relia:DecemberFiveTwoThousandTwentyFourMember2024-07-310001663038relia:OctoberTwentyNineTwoThousandTwentyFourOneMember2024-07-310001663038relia:OctoberTwentyNineTwoThousandTwentyFourMember2024-07-310001663038relia:OctoberTwentyEightTwoThousandTwentyFourMember2024-07-310001663038relia:SeptemberTwelveTwoThousandTwentyFourMember2024-07-310001663038relia:AugustTwoTwoThousandTwentyFourMember2024-07-310001663038relia:JuneTwentyFiveTwoThousandTwentyFourMember2024-07-310001663038relia:JuneSeventeenTwoThousandTwentyFourMember2024-07-310001663038relia:MayFiveTwoThousandTwentyFourMember2024-07-310001663038relia:AprilTwentyTwoTwoThousandTwentyFourMember2024-07-310001663038relia:AprilTwoTwoThousandTwentyFourMember2024-07-310001663038relia:MarchFourteenTwoThousandTwentyThreeMember2024-07-310001663038relia:AprilTwentyEighthTwoThousandTwentyThreeMember2024-07-310001663038relia:AprilTwentyEighthTwoThousandTwentyThreeOneMember2024-07-310001663038relia:MayFourTwoThousandTwentyThreeMember2024-07-310001663038relia:JulyThirtyOneTwoThousandTwentyThreeMember2024-07-310001663038relia:SeptemberEightTwoThousandTwentyThreeMember2024-07-310001663038relia:SeptemberElevenTwoThousandTwentyThreeMember2024-07-310001663038relia:SeptemberThirteenTwoThousandTwentyThreeMember2024-07-310001663038relia:SeptemberTwentyTwoThousandTwentyThreeMember2024-07-310001663038relia:SeptemberTwentyNineTwoThousandTwentyThreeMember2024-07-310001663038relia:OctoberElevenTwoThousandTwentyThreeMember2024-07-310001663038relia:OctoberSixteenTwoThousandTwentyThreeMember2024-07-310001663038relia:JanuaryThirtyOneTwoThousandTwentyFourMember2024-07-310001663038relia:FebruaryEightTwoThousandTwentyFourMember2024-07-310001663038relia:FebruaryTwentyOneTwoThousandTwentyFourMember2024-07-310001663038relia:FebruaryTwentyTwoTwoThousandTwentyFourMember2024-07-310001663038relia:JulyThirtyOneTwoThousandTwentyFiveMember2025-07-310001663038relia:FebruaryTwentyEightTwoThousandTwentyFiveMember2024-07-310001663038relia:AprilThirtyTwoThousandTwentyFiveMember2025-07-310001663038relia:MarchFourTwoThousandTwentyFiveMember2025-07-310001663038relia:FebruaryTwentyEightTwoThousandTwentyFiveMember2025-07-310001663038relia:AugustSixteenTwoThousandTwentyFourMember2025-07-310001663038relia:FebruaryElevenTwoThousandTwentyFiveMember2025-07-310001663038relia:DecemberSevenTwoThousandTwentyFourMember2025-07-310001663038relia:DecemberFiveTwoThousandTwentyFourMember2025-07-310001663038relia:OctoberTwentyNineTwoThousandTwentyFourOneMember2025-07-310001663038relia:OctoberTwentyNineTwoThousandTwentyFourMember2025-07-310001663038relia:OctoberTwentyEightTwoThousandTwentyFourMember2025-07-310001663038relia:SeptemberTwelveTwoThousandTwentyFourMember2025-07-310001663038relia:AugustTwoTwoThousandTwentyFourMember2025-07-310001663038relia:JuneTwentyFiveTwoThousandTwentyFourMember2025-07-310001663038relia:JuneSeventeenTwoThousandTwentyFourMember2025-07-310001663038relia:MayFiveTwoThousandTwentyFourMember2025-07-310001663038relia:AprilTwentyTwoTwoThousandTwentyFourMember2025-07-310001663038relia:AprilTwoTwoThousandTwentyFourMember2025-07-310001663038relia:MarchFourteenTwoThousandTwentyThreeMember2025-07-310001663038relia:AprilTwentyEighthTwoThousandTwentyThreeMember2025-07-310001663038relia:AprilTwentyEighthTwoThousandTwentyThreeOneMember2025-07-310001663038relia:MayFourTwoThousandTwentyThreeMember2025-07-310001663038relia:JulyThirtyOneTwoThousandTwentyThreeMember2025-07-310001663038relia:SeptemberEightTwoThousandTwentyThreeMember2025-07-310001663038relia:SeptemberElevenTwoThousandTwentyThreeMember2025-07-310001663038relia:SeptemberThirteenTwoThousandTwentyThreeMember2025-07-310001663038relia:SeptemberTwentyTwoThousandTwentyThreeMember2025-07-310001663038relia:SeptemberTwentyNineTwoThousandTwentyThreeMember2025-07-310001663038relia:OctoberElevenTwoThousandTwentyThreeMember2025-07-310001663038relia:OctoberSixteenTwoThousandTwentyThreeMember2025-07-310001663038relia:JanuaryThirtyOneTwoThousandTwentyFourMember2025-07-310001663038relia:FebruaryEightTwoThousandTwentyFourMember2025-07-310001663038relia:FebruaryTwentyOneTwoThousandTwentyFourMember2025-07-310001663038relia:FebruaryTwentyTwoTwoThousandTwentyFourMember2025-07-310001663038relia:FebruaryTenTwoThousandTwentyThreeOneMember2024-07-310001663038relia:FebruaryTenTwoThousandTwentyThreeMember2024-07-310001663038relia:JulyTwentyTwoThousandTwentyOneMember2024-07-310001663038relia:JulyTwentyTwoThousandTwentyOneMember2025-07-310001663038relia:FebruaryTenTwoThousandTwentyThreeMember2025-07-310001663038relia:FebruaryTenTwoThousandTwentyThreeOneMember2025-07-310001663038relia:JuneFourteenTwoThousandTwentyOneMember2025-07-310001663038relia:JuneFourteenTwoThousandTwentyOneMember2024-07-310001663038us-gaap:RetainedEarningsMember2025-07-310001663038relia:StockPayableMember2025-07-310001663038us-gaap:AdditionalPaidInCapitalMember2025-07-310001663038us-gaap:CommonStockMember2025-07-310001663038relia:SeriesBPreferredSharesMember2025-07-310001663038us-gaap:RetainedEarningsMember2024-08-012025-07-310001663038relia:StockPayableMember2024-08-012025-07-310001663038us-gaap:AdditionalPaidInCapitalMember2024-08-012025-07-310001663038us-gaap:CommonStockMember2024-08-012025-07-310001663038relia:SeriesBPreferredSharesMember2024-08-012025-07-310001663038us-gaap:RetainedEarningsMember2024-07-310001663038relia:StockPayableMember2024-07-310001663038us-gaap:AdditionalPaidInCapitalMember2024-07-310001663038us-gaap:CommonStockMember2024-07-310001663038relia:SeriesBPreferredSharesMember2024-07-310001663038us-gaap:RetainedEarningsMember2023-08-012024-07-310001663038relia:StockPayableMember2023-08-012024-07-310001663038us-gaap:AdditionalPaidInCapitalMember2023-08-012024-07-310001663038us-gaap:CommonStockMember2023-08-012024-07-3100016630382023-07-310001663038us-gaap:RetainedEarningsMember2023-07-310001663038relia:StockPayableMember2023-07-310001663038us-gaap:AdditionalPaidInCapitalMember2023-07-310001663038us-gaap:CommonStockMember2023-07-310001663038relia:SeriesBPreferredSharesMember2023-07-3100016630382023-08-012024-07-310001663038us-gaap:SeriesBPreferredStockMember2024-07-310001663038us-gaap:SeriesBPreferredStockMember2025-07-310001663038us-gaap:SeriesAPreferredStockMember2024-07-310001663038us-gaap:SeriesAPreferredStockMember2025-07-3100016630382024-07-3100016630382025-07-3100016630382025-11-1000016630382025-01-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 10-K

(Mark One)

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the fiscal year ended July 31, 2025

	or

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ________ to _________

~~[X]~~Quantumzyme ~~ANNUAL~~Corp. ~~REPORT UNDER SECTION 13 OR 15~~(d)Exact OFname ~~THE~~of ~~SECURITIES~~registrant ~~EXCHANGE~~as ~~ACT~~specified OFin ~~1934~~its charter)

For the fiscal year ended July 31, 2018

Nevada	000-56725	N/A
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

[15656 ]Bernardo ~~TRANSITION~~Center ~~REPORT~~Drive ~~UNDER~~Suite ~~SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~801

~~For the~~San ~~transition~~Diego, ~~period~~CA ~~from ________________ to________________~~92127

~~Commission file~~Tel.: ~~number 333~~858-~~208934~~203-0312

~~RELIANT~~(Address, ~~SERVICE~~including ~~INC.~~zip ~~(Exact~~code, ~~name~~and oftelephone ~~registrant~~number, asincluding ~~specified~~area incode, ~~its~~of ~~charter~~registrant's principal executive offices)

Nevada		36-4806481
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Securities registered pursuant to Section 12(b) of the Act: None

~~Room 1202,~~Securities ~~No.~~registered ~~22-2625~~pursuant ~~Pingliang~~to ~~Road~~Section 12(g) of the Act: Common Stock, $0.00001 Par Value

Yangpu District, Shanghai, China

(Address of registrant’s principal executive offices)

Registrant’s telephone number, including area code: +86-13166667122

Securities registered under Section 12(b) of the Act:

None N/A Title of each class Name of each exchange on which registered

Securities registered under Section 12(g) of the Act:

Common Stock, $0.001 par value

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ~~[ ]~~ ☐ No ~~[X]~~☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or ~~Section~~ 15(d) of the Act.

Yes ~~[ ]~~ ☐ No ~~[X]~~☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T ~~(§232.405 of this chapter)~~ during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒ No ☐

~~Yes [X]~~Indicate Noby ~~[ ]~~check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

~~Indicate by~~Large ~~check~~Accelerated ~~mark~~Filer if☐ ~~disclosure~~Accelerated ofFiler ~~delinquent~~☐ ~~filers pursuant to Item 405 of Regulation S~~Non-KAccelerated isFiler ~~not~~☒ ~~contained~~Smaller ~~herein,~~Reporting ~~and~~Company ~~will~~☒ ~~not be~~Emerging ~~contained,~~growth tocompany ~~the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]~~☒

~~Indicate by~~If ~~check~~an ~~mark~~emerging ~~whether~~growth ~~the~~company, ~~registrant~~indicate isby acheck ~~large~~mark ~~accelerated~~if ~~filer,~~the anregistrant ~~accelerated~~has ~~filer,~~elected anot ~~non-accelerated~~to ~~filer,~~use orthe aextended ~~smaller reporting~~transition ~~company.~~period ~~See~~for ~~the~~complying ~~definitions~~with ofany ~~“large~~new ~~accelerated~~or ~~filer,”~~revised ~~“accelerated~~financial ~~filer”~~accounting ~~and~~standards ~~“smaller reporting~~provided ~~company”~~pursuant into ~~Rule~~Section ~~12b-2~~13(a) of the Exchange Act. ☐

~~Large~~Indicate ~~accelerated~~by ~~filer~~check [mark ]whether ~~Accelerated~~the ~~filer~~registrant [has ]filed ~~Non-accelerated~~a ~~filer~~report [on ]and ~~(Do~~attestation ~~not~~to ~~check~~its ifmanagement’s aassessment ~~smaller~~of the effectiveness of its internal control over financial reporting ~~company~~under Section 404(b) ~~Smaller~~of ~~reporting~~the ~~company~~Sarbanes-Oxley ~~[X]~~Act ~~Emerging~~(15 ~~growth~~U.S.C. ~~company~~7262(b)) ~~[X]~~by the registered public accounting firm that prepared or issued its audit report. ☐

If an ~~emerging~~securities ~~growth~~are ~~company,~~registered ~~indicate~~pursuant byto ~~check~~Section ~~mark~~12(b) ifof the ~~registrant~~Act, ~~has~~indicate ~~elected~~by ~~not~~check tomark ~~use~~whether the ~~extended~~financial ~~transition~~statements ~~period~~of ~~for complying~~the ~~with~~registrant ~~any~~included ~~new~~in orthe ~~revised~~filing ~~financial~~reflect ~~accounting~~the ~~standards~~correction ~~provided~~of ~~pursuant~~an error to ~~Section~~previously ~~13(a)~~issued offinancial ~~the Exchange Act~~statements. ☐

~~[ ]~~Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ~~Exchange~~ Act). Yes ☐ No ☒

~~Yes [X]~~The Noaggregate ~~[ ]~~market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $4,327,050. Shares of common stock held by each executive officer and director and by each person who owns 10% or more of the outstanding common stock of the registrant have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. Without acknowledging that any individual director of registrant is an affiliate, all directors have been included as affiliates with respect to shares owned by them.

As of November 2010, ~~2018~~2025, ~~the~~there ~~registrant had 5~~were 38,~~015~~962,~~000~~050 ~~shares~~ of the registrant’s common stock ~~issued and~~ outstanding. ~~No market value has been computed based upon the fact that no active trading market had been established as of November 20, 2018.~~

QUANTUMZYME CORP.

Report on Form 10-K

TABLE OF CONTENTS

	PART I
			Page
ITEM 1	Business	3
PART I.
ITEM 1A	Risk Factors	7
Item 1.	Business		3
ITEM 1B	Unresolved Staff Comments	7
Item 1A.	Risk Factors		14
ITEM 2	Properties	7
Item 1B.	Unresolved Staff Comments		22
ITEM 3	Legal Proceedings	7
Item 1C	Cybersecurity		22
ITEM 4	Mine Safety Disclosures	7
Item 2.	Properties		22
	PART II
Item 3.	Legal Proceedings		22
ITEM 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	8
Item 4.	Mine Safety Disclosures		22
ITEM 6	Selected Financial Data	9
PART II.			23
ITEM 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities		23
ITEM 7A	Quantitative and Qualitative Disclosures about Market Risk	13
Item 6.	[Reserved]		24
ITEM 8	Financial Statements and Supplementary Data	13
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		25
ITEM 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	13
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk		25
ITEM 9A	Controls and Procedures	14
Item 8.	Financial Statements and Supplementary Data		25
ITEM 9B	Other Information	15
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure		25
	PART III
Item 9A.	Controls and Procedures		25
ITEM 10	Directors, Executive Officers and Corporate Governance	16
Item 9B.	Other Information		26
ITEM 11	Executive Compensation	18
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections		26
ITEM 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	19
PART III.			27
ITEM 13	Certain Relationships and Related Transactions, and Director Independence	19
Item 10.	Directors, Executive Officers and Corporate Governance		27
ITEM 14	Principal Accounting Fees and Services	20
Item 11.	Executive Compensation		29
	PART IV
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters		30
ITEM 15	Exhibits, Financial Statement Schedules	21
Item 13.	Certain Relationships and Related Transactions, and Director Independence		30
ITEM 16	Form 10-K Summary	21
Item 14.	Principal Accountant Fees and Services		30
PART IV.			31
Item 15.	Exhibits and Financial Statement Schedules		31
Item 16.	Form 10-K Summary

~~FORWARD-LOOKING STATEMENTS~~2 Table of Contents

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. These risks and uncertainties include the following:

● The availability and adequacy of working capital to meet our requirements; ● Actions taken or omitted to be taken by legislative, regulatory, judicial and other governmental authorities; ● Changes in our business strategy or development plans; ● The availability of additional capital to support capital improvements and development; ● Other risks identified in this report and in our other filings with the Securities and Exchange Commission or the SEC; and ● The availability of new business opportunities.

This Annual Report on Form 10-K should be read completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K and should be evaluated with consideration of any changes occurring after the date of this Annual Report on Form 10-K. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Term

Except as otherwise indicated by the context hereof, references in this report to “Company,” “Reliant,” “we,” “us” and “our” are references to Reliant Service Inc. All references to “USD” or United States Dollars refer to the legal currency of the United States of America.

PART I

~~ITEM 1.~~FORWARD ~~BUSINESS~~LOOKING STATEMENTS

~~Our~~ Except for statements of historical fact, certain information described in this Annual Report on Form 10-K (“Annual Report”) contains “forward-looking statements” that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would” or similar words. The statements that contain these or similar words should be read carefully because these statements discuss the Company’s future expectations, including its expectations of its future results of operations or financial position, or state other “forward-looking” information. Quantumzyme Corp. believes that it is important to communicate its future expectations to its investors. However, there may be events in the future that the Company is not able to accurately predict or to control. Further, the Company urges you to be cautious of the forward-looking statements which are contained in this Annual Report because they involve risks, uncertainties and other factors affecting its operations, market growth, service, products, and licenses. The risk factors in the section captioned “Risk Factors” in Item 1A of the Company’s Annual Report, as well as other cautionary language in this Annual Report, describe such risks, uncertainties and events that may cause the Company’s actual results and achievements, whether expressed or implied, to differ materially from the expectations the Company describes in its forward-looking statements. The occurrence of any of the events described as risk factors could have a material adverse effect on the Company’s business, results of operations and financial position.

~~Reliant was~~ITEM ~~incorporated on March 20, 2015, under the laws of the State of Nevada~~1. ~~Its business was to provide file cabinet distribution services~~BUSINESS.

~~A change of control of Reliant took place on May 10, 2018. On that date, Stanislav Augustin sold 4,000,000 shares of common stock of the~~ Company to Zhu Ming, Wang Ye, Ma Chao, Piao Guigen, Zu Tianliang, Zhang Yulong, Yao Hongtao, Zhu Yukun, Chen Wei, Wu Chao, Wang Qinyu, Gao Hang, Ge Shiyang, Li Shuang, Wang Mingyu, Cao Delong, Jin Tong, Wang Zhiqian, Yang Wanli, Zhang Ye and Zhu Haoyu (the “Change of Control”). In connection with the Change of Control, Stanislav Augustin released the Company from all debts owed to him.Overview

~~Upon the~~Quantumzyme ~~Change~~Corp., ofis ~~Control,~~a ~~Stanislav~~biotransformation ~~Augustin~~company, ~~the~~focused ~~sole~~on ~~director~~clean and ~~officer~~green chemistry. Specifically, Quantumzyme is in the business of developing engineered enzymes in the ~~Company,~~application ~~resigned~~of ~~immediately~~active pharmaceutical ingredients (“API”) production. ~~Accordingly~~As we move forward, ~~Stanislav Augustin~~we ~~ceased~~intend to beexpand beyond the ~~Company’s~~API ~~President,~~marketplace ~~Chief~~and ~~Executive~~engineer ~~Officer~~enzymes for the use and deployment in other business sectors such as fragrance and flavors, ~~Treasurer~~climate impacting applications like sustainable materials, ~~Secretary~~plastic degradation and ~~Director~~carbon capture. ~~Upon~~In the ~~Change~~ development and engineering of ~~Control~~enzymes, ~~Mr.~~we ~~Zhu~~conduct ~~Ming~~research ~~consented~~ to ~~act~~enhance asenzyme ~~the~~activity, ~~new President~~selectivity, ~~Chief~~and ~~Executive~~specificity ~~Officer~~by applying novel quantum mechanics, ~~Chief~~molecular ~~Financial~~modelling, ~~Officer~~and engineering approaches. Our goal is to help to foster a clean, ~~Treasurer~~healthy, ~~Secretary~~ and ~~Chairman~~well protected environment supporting a sustainable society and economy. Ultimately, we want to fulfil our vision by developing a focused approach to aid all chemical companies to harness the power of technology by simplifying complex chemistry and reducing the ~~Board~~number of ~~Directors~~steps by implementing scientific rationale like quantum mechanics in biology. As we continue to develop and implement our plan of operation, we intend to establish ourselves as industry leaders by solving complex chemistry problems in the ~~Company~~pharmaceutical, fragrances, and flavors sectors.

~~On June~~As ~~19,~~of ~~2018,~~ the ~~Company~~date ~~entered~~hereof, ~~into~~we ahave ~~share~~engineered ~~exchange~~our ~~agreement~~first ~~(the~~product, ~~“SEA”)~~which ~~with~~is ~~Coolpaul~~an ~~Holding~~enzyme ~~Group~~for ~~Limited (“CPRC”)~~use ~~and~~in ~~five~~pharmaceutical ~~shareholders,~~API ~~Xin~~production ~~Liu,~~of ~~Positive~~Ibuprofen. ~~Energy Limited~~Specifically, ~~Newpoch~~our ~~Limited,~~initial ~~Grow~~product Upis ~~Limited~~targeted ~~and~~at ~~Every~~select ~~Limited (the~~pharmaceutical ~~“Five~~companies ~~Shareholders”),~~ who ~~collectively~~produce ~~hold~~generic ~~100%~~drugs. ofWe ~~the~~are ~~issued~~in ~~and~~the ~~outstanding~~process ~~capital stock~~ of ~~CPRC.~~identifying ~~Pursuant to~~3rd ~~the~~party ~~SEA,~~manufacturers ~~the~~and ~~Company~~distributors ~~agreed~~that toare ~~issue~~capable ~~60,000,000~~of ~~shares~~manufacturing (the ~~“New~~enzyme ~~Shares”)~~on ofa ~~the~~large ~~Company’s~~scale ~~common~~and ~~stock~~distributing to the ~~Shareholders,~~product ~~which~~within ~~collectively~~the ~~would~~relevant ~~represent 92~~markets.3% As of the ~~issued~~date ~~and~~of ~~outstanding~~this ~~common~~report, ~~stock~~we ofhave ~~the~~not ~~Company~~filed ~~immediately after~~for ~~the~~patent ~~closing~~protection offor ~~the~~this ~~SEA,~~product inand ~~exchange~~do ~~for~~not ~~400,000,000~~anticipate ~~ordinary~~doing ~~shares~~so ofin ~~CPRC (~~the ~~“CPRC~~near ~~Shares”),~~future. ~~representing 100%~~At ofthis time, the ~~issued~~costs ~~share~~associated ~~capital~~with ofpatent ~~CPRC~~prosecution outweigh the anticipated benefits.

~~On September~~Industry 11, 2018, the Company, CPRC, and the Five Shareholders agreed to terminate the SEA dated June 19, 2018 and entered into a Termination and Release Agreement (the “Termination Agreement”). The SEA includes no penalties material to the Company which result from its termination.Overview

~~Our Current~~Enzyme ~~Business~~engineering is a dynamic and evolving field within the broader biotechnology sector, focusing on the modification and optimization of enzymes for various industrial, medical, and environmental applications. Enzyme engineering plays a pivotal role in advancing industrial processes, healthcare solutions, and environmental technologies. The industry's success is driven by continuous innovation, interdisciplinary collaboration, and the ability to address challenges associated with enzyme specificity, stability, and regulatory compliance.

~~Through May~~Enzymes ~~10,~~are ~~2018,~~proteins ~~the~~that ~~Company’s~~act ~~primary~~as ~~business~~catalysts, ~~activity~~facilitating ~~was~~and toaccelerating ~~provide~~chemical ~~file~~reactions ~~cabinet~~in ~~distribution~~living ~~services~~organisms. ~~Going~~Enzyme ~~forward, the~~engineering ~~Company’s~~involves ~~operations~~modifying ~~will~~these beproteins ~~determined~~to ~~and~~enhance ~~structured~~their ~~by the new investor group as such~~performance, ~~at May 10~~stability, ~~2018,~~and ~~the~~specificity ~~Company accounted~~ for ~~all~~targeted ofapplications. ~~its~~Enzyme ~~assets,~~engineering ~~liabilities~~contributes ~~and~~to ~~results~~advancements ofin ~~operations~~sustainable upand togreen ~~May 10~~technologies, ~~2018~~improving ~~as discontinued operations. Following~~ the ~~Change~~efficiency of ~~Control,~~industrial ~~the~~processes ~~Company~~while ~~became~~minimizing aenvironmental ~~shell~~impact. ~~company~~Companies ~~without~~in ~~any~~this ~~significant~~field ~~assets~~often orcollaborate ~~operations.~~with Weindustries ~~plan~~such toas ~~grow~~biotechnology, ~~our~~pharmaceuticals, ~~revenue~~ agriculture, and ~~operating~~environmental ~~income~~science ~~through~~to ~~acquisitions~~address ofspecific ~~additional~~challenges ~~operating~~and ~~companies~~develop ~~and~~innovative ~~facilities~~solutions.

~~Discontinued Operations~~3 Table of Contents

~~Until~~ Key factors contributing to the ~~Change~~industry’s growth include the expansion of ~~Control~~biotechnological capabilities, wethe ~~were~~increasing indemand for sustainable solutions, and the ~~business~~versatility of ~~providing~~enzymes ~~file~~across ~~cabinet~~various ~~distribution~~applications. ~~services~~As the enzyme engineering field continues to evolve, it holds promise for addressing complex global challenges and driving advancements in biotechnology, offering a wide array of opportunities for research, development, and commercialization.

~~We signed~~Here's ~~supplier~~an ~~agreements~~overview ~~with multiple suppliers to ensure the quality~~ and ~~consistency~~summary of ~~our merchandise. All agreements have been filed as exhibits to our Registration Statement on Form S-1 and~~ the ~~details~~enzyme ~~are~~engineering ~~set out in each agreement.~~industry:

3· Enzyme engineering leverages advances in genetic engineering, protein design, and computational biology to enhance the performance of enzymes; · Enzymes find applications across diverse industries, including food and beverage, pharmaceuticals, biofuels, textiles, agriculture, and environmental remediation; · Ongoing R&D efforts focus on discovering new enzymes, optimizing existing ones, and addressing challenges such as substrate specificity, stability, and scalability; · Enzyme engineering companies typically operate globally, catering to international markets and collaborating with industries worldwide to address specific needs; · The industry aligns with sustainability goals, contributing to the development of green technologies by improving efficiency, reducing environmental impact, and promoting sustainable practices; · Regulatory considerations are paramount, especially in industries like pharmaceuticals and food, where safety and compliance standards play a crucial role in market entry; and, · Companies invest in securing intellectual property rights through patents to protect innovations, creating a competitive edge in the market.

~~We sourced~~Engineering ~~our~~enzymes ~~file~~involves ~~cabinets~~leveraging ~~from~~biotechnological ~~Chinese~~techniques ~~manufacturers.~~to ~~Our~~modify ~~customers paid for the product~~ and weoptimize ~~paid~~enzymes ~~the~~for ~~suppliers.~~various ~~Our~~industrial ~~customers could~~applications, ~~choose~~including ~~to have their orders delivered to their respective business locations or they could pick up their orders at~~ the ~~suppliers’ business~~following ~~locations.~~applications:

~~Product Description~~Industrial Applications: Enzymes play a crucial role in industrial processes such as food and beverage production, biofuel manufacturing, textiles, and more. Enzyme engineering companies focus on developing enzymes that enhance efficiency, reduce costs, and improve overall performance in these processes.

~~Filing cabinets~~Biopharmaceuticals: Enzymes are ~~office~~utilized ~~equipment~~in ~~used~~the ~~for~~production ~~document~~of ~~storage purposes~~biopharmaceuticals. ~~The~~Companies ~~two~~in ~~most~~this ~~common~~sector ~~types~~engage ofin ~~filing~~enzyme ~~cabinets~~engineering ~~are~~to ~~vertical~~create ~~cabinets and~~enzymes ~~lateral cabinets. A vertical filing cabinet has drawers~~ that ~~extend~~are ~~from~~better ~~the~~suited ~~short~~for ~~side (typically 15 inches) of~~ the ~~cabinet. A~~production ~~lateral filing cabinet has drawers that extend from the long side (various lengths)~~ of ~~the~~therapeutic ~~cabinet.~~proteins Inand ~~the United States~~drugs, ~~filing cabinets~~contributing ~~are usually built~~ to ~~accommodate~~advancements ~~8.5~~ in ×the 11pharmaceutical ~~in paper size~~industry.

~~Office filing~~Diagnostic ~~cabinets~~and ~~are~~Research ~~usually~~Tools: ~~made~~Enzymes ofare ~~sheet~~essential ~~metal~~components orof ~~wood.~~diagnostic ~~The~~tests ~~drawers~~and ~~use~~research atools ~~drawer~~in ~~slide~~various ~~to facilitate smooth opening~~fields. ~~The~~Enzyme ~~draw slides~~engineering ~~include~~companies anwork ~~out stop to prevent the drawer from being pulled out completely. To open a drawer~~ on ~~most~~creating ~~metal~~enzymes ~~filing~~with ~~cabinets, a~~improved ~~small~~sensitivity ~~sliding mechanism known as a thumb latch must be pressed to start releasing~~ and ~~opening~~specificity ~~the drawer. Drawers usually come with a handle~~ for ~~easier~~diagnostic ~~pulling~~applications, ~~movements.~~catering ~~People~~to ~~can usually find a label holder on~~ the ~~front~~healthcare ~~side of the drawer. This allows people to mark up~~ and ~~identify~~research ~~the contents of the drawer easily~~sectors.

~~Most filing~~Bioremediation ~~cabinets use locks to prevent unauthorized access. Typically, filing cabinets use two types of locks—cam locks~~ and ~~plunger~~ ~~locks.~~Environmental ASolutions: ~~cam~~Enzymes ~~lock~~ can be ~~opened~~employed ~~and~~for ~~closed~~environmental ~~with a key that rotates the lock. A plunger lock can be opened with a key and can be closed by merely pressing the body of the lock. Thus~~purposes, asuch ~~plunger~~as ~~lock~~bioremediation ~~allows people~~ to ~~quickly~~clean ~~close~~up ~~and lock several cabinets in a short amount of time~~pollutants. ~~Some~~Enzyme ~~filing~~engineering ~~cabinets have a metal plate or wiring structure at the back of each drawer—this~~ is ~~known~~ asused ~~a follower block. The follower block can be adjusted forward~~ to ~~reduce~~design ~~the~~enzymes ~~length~~that ofare ~~the~~more ~~drawer~~effective soin ~~that~~breaking ~~the~~down ~~file~~specific ~~folders contained~~contaminants, ~~within~~addressing ~~remain~~environmental ~~upright~~challenges and atcreating ~~the~~sustainable ~~front of the drawer for easier access~~solutions.

~~Industry Overview~~Agricultural Innovations: Enzymes find applications in agriculture for soil improvement, crop protection, and more. Enzyme engineering companies may develop enzymes that enhance nutrient availability, promote plant growth, or provide protection against pests, contributing to advancements in agricultural practices.

~~According to~~Research ~~IBISWorld’s~~and ~~Online~~Development: ~~Office~~Enzyme ~~Furniture~~engineering ~~Sales~~involves ~~market~~continuous research ~~report~~and ~~the~~development ~~Industry~~efforts ~~Statistics~~to &discover ~~Market~~novel ~~Size~~enzymes ~~(source:~~and ~~www~~optimize existing ones.~~ibisworld~~ This ongoing innovation is crucial for staying competitive in the biotechnology sector and addressing emerging challenges.~~com):~~

~~Revenue $10bn~~4 Table of Contents

~~Annual Growth~~Collaboration ~~09-14~~and 13Partnerships: Companies in enzyme engineering often collaborate with industries such as biotechnology, pharmaceuticals, agriculture, and environmental science.8% Collaborations and partnerships help address specific challenges, pool resources, and bring innovative enzyme solutions to market.

~~Employment 6~~Commercialization of Intellectual Property: Enzyme engineering companies invest in intellectual property protection for their innovations. They generate revenue by commercializing patented enzymes,~~622~~ licensing technologies, and offering specialized enzyme solutions to industries.

~~Businesses 3~~Global Market Presence: Many enzyme engineering companies operate globally,~~178~~ catering to diverse markets and industries. This global presence allows them to tap into different economic environments, expand market reach, and diversify revenue streams.

~~Industry Analysis~~Adaptation &to ~~Industry~~Market Trends: ~~Revenue~~Enzyme ~~for~~engineering ~~the~~companies ~~Online~~need ~~Office~~to ~~Furniture~~stay ~~Sales~~adaptive ~~industry has grown in the past five years as a post-recession recovery of corporate profit led more businesses~~ to ~~expand~~market ~~employment~~trends and ~~office~~technological ~~space~~advancements. ~~Additionally,~~This ~~the~~includes ~~industry~~embracing ~~experienced growth~~sustainable inand ~~line~~green ~~with the e-commerce sector as a whole~~technologies, asaligning ~~more~~with ~~brick-and-mortar retailers focus on their internet presence and an increasing share of consumers opt to purchase~~ consumer ~~goods online. These trends drove our revenue growth~~preferences, ~~albeit~~and ataddressing aevolving ~~slower pace,~~industry ~~prior to our Change in Control~~needs.

~~Industry Report~~Engineering -enzymes ~~Industry~~for ~~SWOT~~profit ~~Analysis:~~involves ~~The Online Office Furniture Sales industry is in the growth stage of its life cycle, largely because of growth in e-commerce as~~ a ~~percentage~~multidimensional ~~of total retail sales. In the 10 years to 2007 the industry’s contribution to the overall economy~~approach, ~~which~~including ~~is measured by industry value added (IVA)~~innovation, ~~is expected to increase an average of 10.5% annually~~collaboration, ~~compared~~ ~~with~~and ~~annualized~~strategic ~~GDP~~market ~~growth of 2~~positioning.5% ~~during~~As ~~the~~we ~~same~~move ~~period.~~our ~~This~~plan ~~indicates that the industry is in the growth phase~~ of ~~its~~ ~~life~~operation ~~cycle~~forward, ~~because~~we ~~its~~intend ~~contribution~~ to ~~GDP~~contribute isto ~~rising~~sustainable ~~over~~industrial ~~the~~practices, ~~10-year~~advancements ~~period.~~in ~~Increasing~~healthcare, ~~industry participation~~ and ~~growing market~~environmental ~~penetration~~solutions ~~also~~while ~~indicate~~seeking ~~that~~financial ~~the~~success ~~industry~~through ~~is in~~ the ~~growth~~commercialization ~~phase~~ of ~~its~~enzyme-based ~~life~~products ~~cycle~~and services.

4While enzyme engineering has made significant progress, there are still challenges and limitations associated with the field. Some common problems in engineering enzymes include:

~~Employees~~· Achieving high substrate specificity and selectivity can be challenging. Designing enzymes that only catalyze a specific reaction without side reactions can be complex; · Enzymes may undergo denaturation or lose activity under certain conditions, such as extremes of pH, temperature, or in the presence of organic solvents. Improving stability is crucial for industrial applications; · Some enzymes require cofactors for their activity. Designing enzymes that function effectively without specific cofactors or finding cost-effective ways to provide cofactors can be challenging; · Immobilizing enzymes for industrial use can be problematic. Issues may include maintaining high catalytic efficiency, avoiding mass transfer limitations, and preserving the structural integrity of the immobilized enzyme; · Transitioning from laboratory-scale experiments to large-scale industrial production can be challenging. Factors such as cost, scalability, and maintaining enzyme activity at scale need careful consideration; · Producing engineered enzymes on a large scale can be expensive. Finding cost-effective methods for enzyme production, purification, and recovery is crucial for commercial viability; · Enzymes used in various applications, particularly in the food and pharmaceutical industries, may face regulatory hurdles. Compliance with safety and regulatory standards can pose challenges; · Achieving the correct three-dimensional structure is essential for enzyme activity. Issues related to protein folding and misfolding can impact the efficiency of engineered enzymes; · Despite advances in structural biology, understanding the intricate relationships between enzyme structure and function remains a complex task. Predicting the effects of specific mutations on enzyme activity can be challenging; · Enzymes may be susceptible to inhibition by various factors, including competitive inhibitors or changes in environmental conditions. Overcoming inhibition challenges is essential for maintaining consistent enzyme performance; · Enzymes often need to function under diverse conditions in different industrial processes. Designing enzymes that are versatile and effective across a range of conditions can be challenging; and, · As enzyme engineering advances, ethical considerations related to the potential misuse of engineered enzymes or unintended environmental impacts may arise.

~~We currently~~5 ~~have~~Table noof ~~employees. Our sole officer and director Zhu Ming handles the company’s day to day operations.~~Contents

~~Insurance~~We will continually work to address these challenges through innovative genetic engineering, protein design, and bioprocessing techniques. Overcoming these problems is crucial for unlocking the full potential of engineered enzymes in various industrial, medical, and environmental applications.

We do not have any insurance policies. Thus, if we are made a defendant of a legal action, we may not be financially viable to defend ourselves and if a judgment were to be rendered against us, it would materially impact our business operations.Glossary

~~Employees; Identification~~The offollowing ~~Certain~~terms ~~Significant~~shall ~~Employees~~have the meanings set forth below:

~~We are~~API ameans ~~development~~an ~~stage~~Active ~~company~~Pharmaceutical ~~and~~Ingredient ~~currently~~(API), ~~have~~also noknown ~~employees.~~as ~~Zhu~~a ~~Ming~~drug substance, ~~our~~is ~~sole~~a ~~officer~~specific ~~and~~chemical ~~director,~~or biological substance that is aresponsible ~~non-employee~~for ~~officer and~~the ~~director~~therapeutic effect of ~~the~~a ~~Company~~pharmaceutical drug. WeIt ~~intend~~is tothe ~~hire~~biologically ~~employees~~active oncomponent anof asa ~~needed~~medication ~~basis~~that asproduces the ~~business~~desired ~~grows~~pharmacological activity in the body.

~~Offices~~Biotransformation refers to the chemical alteration of compounds or substances by using enzymes. It involves the enzymatic process(es) that occur in various biological systems, such as microorganisms, plants, animals, and humans. Biotransformation can occur through a single or a series of enzymatic reactions, resulting in the conversion of one compound into another. Biotransformation can also be utilized for the production of valuable compounds, such as pharmaceuticals, flavors, and fragrances, through the use of Biocatalysts.

~~The Company’s~~Biocatalysis ~~principal~~refers ~~offices~~to the use of natural catalysts, primarily enzymes, to facilitate chemical reactions. Enzymes are ~~located~~highly atefficient ~~Room~~biocatalysts ~~1202~~that accelerate the rate of chemical reactions without being consumed in the process. Biocatalysis offers several advantages over traditional chemical catalysts, Noincluding milder reaction conditions, greater selectivity, and reduced environmental impact. ~~22-2625~~Enzymes ~~Pingliang~~can ~~Road~~catalyze a wide range of reactions, ~~Yangpu~~including ~~District~~oxidation, ~~Shanghai~~reduction, ~~China~~hydrolysis, and synthesis of complex molecules. ~~Our telephone~~Biocatalysis ~~number~~finds isapplications ~~+86-13166667122~~in various industries, including pharmaceuticals, biotechnology, food and beverage, and environmental sectors. It plays a crucial role in the production of pharmaceutical intermediates, biofuels, fine chemicals, and other valuable products.

~~Government Regulation~~Insilico refers to processes or experiments that are conducted or simulated using computer models rather than in a traditional laboratory setting such as in vitro (in glass) experiments done in a lab and in vivo (in living organisms) experiments. As used herein, insilico methods involve using computational techniques to analyze chemical compounds, predict their properties, and simulate their interactions.

~~We are~~Legacy ~~required~~reactions refer to ~~comply~~a ~~with~~chemical ~~all~~reaction ~~regulations,~~or ~~rules~~process ~~and~~that ~~directives~~has ofbeen ~~governmental~~used ~~authorities~~historically ~~and~~or ~~agencies~~traditionally infor ~~any~~a ~~jurisdiction which~~particular wepurpose ~~would~~but ~~conduct~~is ~~activities~~now considered outdated or less commonly employed due to advancements in ~~the~~technology, ~~future~~efficiency, or sustainability. ~~Following~~Legacy ~~the~~chemical ~~Change~~reactions ofinclude ~~Control~~older, ~~the~~conventional, ~~Company~~or ~~became~~less aenvironmentally ~~shell~~friendly ~~company~~methods ~~without~~that ~~any significant~~have ~~assets~~been replaced or ~~operations~~improved upon by newer, more efficient, and greener alternatives. ~~There~~These ~~are~~legacy ~~therefore~~reactions might have been widely used in the past but are no ~~required~~longer ~~government~~favored ~~approvals~~due ~~present~~to ~~that~~factors wesuch ~~need~~as ~~approval~~low ~~from~~yields, orhazardous ~~any existing~~reagents, ~~government~~high ~~regulation~~energy onrequirements, ~~our~~or ~~business~~significant waste generation.

~~Copyrights, Patents,~~The ~~Trademarks~~Quantumzyme Solution.

~~We currently~~Our ~~have~~Solution ~~not~~is ~~obtained~~Biocatalysis ~~any~~through ~~copyrights~~engineered enzymes. Engineering enzymes involves the application of scientific principles and techniques to modify and optimize the structure and function of enzymes for specific purposes. Historically, ~~patents~~engineering orenzymes ~~trademarks~~using legacy reactions and traditional processes that involves hazardous chemicals, high pressure, high temperature, which leads to lot of waste generation. WeNot only do ~~not~~traditional ~~anticipate~~methods ~~filing~~cause ~~any~~significant ~~copyright~~pollution orand ~~trademark~~are ~~applications related~~highly toinefficient, ~~any~~but ~~assets~~traditional ~~over~~processes ~~the~~also ~~next~~yield 12poor ~~months~~results and many inefficiencies, multiple impurities, metal catalysts, and hazardous waste. Quantumzyme addresses this problem by leveraging biology and evolution.

~~Research~~ As environmental, social, and ~~Development~~governance (ESG) investing becomes a factor used by socially conscious investors to screen potential investments and sustainability become key focus areas, our solution is perfect for progressive and accountable organizations and industry leaders. Our solution offers following advantages:

~~We have~~Traditional ~~not~~Process ~~spent~~The ~~any~~Quantumzyme ~~money~~Solution ~~during~~- ~~each~~Biocatalysis of· ~~the~~Hazardous ~~last~~chemicals· ~~two~~High ~~fiscal~~Pressure ~~years~~High onTemp· ~~research~~Wastage ~~and~~· ~~development~~Engineered ~~activities.~~Enzyme Catalyst· Low Pressure -Lower Temp· Minimal Waste Disadvantages Advantages · High costs· Low potential for increasing yield· High Impurities· Hazardous waste is concern · Low cost· Improved yield & manufacturing efficiency· Sizable reduction in impurities· Reduced hazardous waste· ESG compliance benefits

~~Emerging Growth~~6 ~~Company~~Table ~~Status~~of ~~under the JOBS Act~~Contents

~~Reliant qualifies~~Solution ~~as an “emerging growth company” as defined in the Jumpstart our Business Startups Act (the “JOBS Act”).~~Delivery:

~~The JOBS~~We ~~Act~~believe ~~creates~~that athe ~~new~~solution ~~category~~is ofdelivered ~~issuers~~through ~~known~~IP asdevelopment ~~“emerging~~processes ~~growth~~covering ~~companies.”~~5 ~~Emerging~~steps ~~growth companies are those with annual gross revenues of less than $1.07 billion (~~as ~~indexed~~detailed for inflation) during their most recently completed fiscal year. The JOBS Act is intended to facilitate public offerings by emerging growth companies by exempting them from several provisions of the Securities Act of 1933 and its regulations. An emerging growth company will retain that status until the earliest ofbelow:

The first fiscal year after its annual revenues exceed $1.07 billion;

Phase 1 – Enzyme Discovery.		This is where the reaction of interest is studied to identify appropriate enzyme(s) Wild Type (WT).

Phase 2 – Lab Validation (WT).		In this phase the WT enzyme(s) are validated for various parameters.

Phase 3 – Enzyme Engineering.		In this phase the WT enzyme is engineered for desired objective.

Phase 4 – Lab Validation (ET).		In this phase the Engineered enzyme (ET) is further validated & optimized for the desired objective.

Phase 5 – Scale-up.		In this phase we look forward for Partnership with potential end users to perform activities such as (but not limited to) Scale-up optimization, Performing fermentation batch & Post scale-up optimization.

~~The~~ As we move forward with the implementation and deployment of our plan of operation, our first, ~~fiscal~~and ~~year~~currently ~~after~~only, developed biocatalyst is for use and license in the ~~fifth~~manufacturing ~~anniversary~~of Ibuprofen. Ibuprofen is one of ~~its~~the ~~IPO;~~most produced drugs by volume globally. However, a major issue with the production of Ibuprofen and the legacy reaction of Ibuprofen, although cost effective, is the utilization of a carcinogenic agent as a catalyst which creates effluent and can cause harm to the environment. This has resulted in the production and manufacturing of Ibuprofen being moved offshore to reduce production costs which are directly passed on the consumer. Our goal is to bring back manufacturing capabilities in the USA by making the manufacturing of Ibuprofen greener, cost effective and more environmentally friendly. Currently we are in the process of understanding the market needs, demand supply relationships, technical feasibility, commercial viability, business cases and discussions with potential end users on the impact of benefits that can be derived from the proposed solution. The uniqueness of our approach is a framework that utilizes distinct techniques with a combination of insilico and invitro techniques catering to specific biocatalysts requirements. We intend to help to foster a clean, healthy, and well protected environment supporting a sustainable society and economy.

~~The date~~We onintend ~~which~~to ~~the~~license ~~company~~our ~~has~~engineered ~~issued~~enzyme ~~more~~to ~~than~~major $1API ~~billion~~manufacturers and Pharma companies. With large scale manufacturing of Ibuprofen API and use of said APIs in ~~non-convertible~~manufacturing ~~debt~~of ~~during~~drugs ~~the~~by ~~previous~~Pharma ~~three-year~~Companies, ~~period;~~we intend to generate revenue from technology transfer and through royalties.

~~The first~~Since ~~fiscal~~the ~~year~~commercialization inof ~~which~~our enzymes will be by and through third party manufacturers, who will ultimately supply the ~~company~~product ~~has~~to athe ~~public~~consumer, ~~float~~such ofmanufacturers will be required to comply with required all governmental regulatory issues, including the FDA and similar governmental agencies. As such Quantumzyme, at least ~~$700~~initially, ~~million~~will not subject to any regulatory or compliance issues. Commercialization of our enzyme, thus, simply entails our licensing the rights to use our developed enzyme to large scale manufacturers and other Pharma Companies.

57 Table of Contents

~~Financial~~ Specifically, Quantumzyme itself will not be directly responsible for obtaining regulatory approvals, at least initially, this burden will fall to the third-party manufacturers commercializing our enzymes. Those manufacturers will be required to comply with all applicable regulatory requirements, including those set forth by the U.S. Food and ~~Audit~~Drug ~~Requirements~~Administration (FDA) and similar regulatory bodies in other jurisdictions. The necessity for regulatory approval depends on the intended application of our enzyme. If used in biopharmaceutical applications, the enzyme may be subject to review and approval under the FDA’s regulatory framework. This could include an evaluation under the Food, Drug, and Cosmetic Act, particularly if the enzyme is classified as an active pharmaceutical ingredient (API) or is incorporated into a regulated drug or biologic product. The approval process may involve pre-market review, safety and efficacy assessments, and adherence to current Good Manufacturing Practices (cGMP). Additionally, any manufacturer supplying enzymes for pharmaceutical use would need to comply with the FDA’s Drug Master File (DMF) requirements, if applicable. For non-pharmaceutical applications, regulatory oversight may vary depending on the specific use case and jurisdiction, with potential requirements from agencies such as the Environmental Protection Agency (EPA) or the European Medicines Agency (EMA), among others. We will continue to work with our third-party manufacturing partners to ensure compliance with all relevant regulatory requirements before commercialization.

~~Under the~~ Ultimately, ~~JOBS~~we ~~Act,~~want ~~emerging~~to ~~growth~~fulfil ~~companies~~our ~~are~~vision ~~subject~~by todeveloping ~~scaled~~a ~~financial~~focused ~~disclosure~~approach ~~requirements.~~to ~~Pursuant~~aid all chemical companies to ~~these~~harness ~~scaled~~the ~~requirements, emerging~~power ~~growth~~of ~~companies~~technology ~~may:~~by simplifying complex chemistry and reducing the number of steps by implementing scientific rationale like quantum mechanics in biology.

~~Provide only~~As ~~two~~a ~~rather~~biotransformation ~~than~~company ~~three~~we ~~years~~will ofconstantly ~~audited~~focus ~~financial~~and ~~statements~~seek to implement our learning in ~~their~~the ~~IPO~~following ~~Registration~~selected ~~Statement;~~areas to continually drive and advance the growth of Quantumzyme:

~~Provide selected~~Understanding ~~financial~~Enzymes: Enzymes ~~data~~are ~~only~~biological ~~for~~catalysts, ~~periods~~typically noproteins, ~~earlier~~that ~~than~~facilitate ~~those~~and ~~included~~accelerate inchemical ~~the~~reactions, ~~IPO~~they ~~Registration~~have ~~Statement~~specific inactive ~~all~~sites ~~SEC~~where ~~filings~~substrates bind, ~~rather~~ ~~than~~and ~~the~~reactions ~~five~~take ~~years~~place. ofEnzymes ~~selected~~are ~~financial~~highly ~~data~~specific ~~normally~~to ~~required;~~their substrates, and their activity can be influenced by various factors.

~~Delay compliance~~Genetic & Protein Engineering: The process often begins with ~~new~~identifying orand ~~revised~~isolating ~~accounting~~genes ~~standards~~that ~~until~~encode ~~they~~for ~~are~~the ~~made~~target ~~applicable~~enzyme. Genetic engineering involves modifying the DNA sequence of these genes using techniques like recombinant DNA technology. Protein engineering focuses on modifying the amino acid sequence of the enzyme to ~~private~~achieve ~~companies;~~desired ~~and~~properties. Techniques include site-directed mutagenesis, where specific amino acids are altered to influence enzyme activity or stability.

~~Be exempted~~Directed ~~from~~Evolution: This ~~compliance~~method ~~with~~mimics ~~Section~~natural ~~404(b)~~selection ofin ~~the~~a ~~Sarbanes-Oxley~~controlled ~~Act,~~laboratory ~~which~~setting ~~requires~~and ~~companies~~our enzymes are subjected to ~~receive~~iterative anrounds ~~outside~~of ~~auditor’s attestation~~mutation ~~regarding~~and ~~the~~selection ~~issuer’s~~to ~~internal~~evolve ~~controls~~desired traits, such as improved substrate specificity or increased stability.

~~Offering Requirements~~Structural Biology: Understanding the three-dimensional structure of enzymes is crucial for rational enzyme design, techniques like X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are used to determine enzyme structures.

~~In addition,~~Computational ~~during~~Biology ~~the~~and ~~IPO~~Bioinformatics: Computational ~~offering~~methods ~~process,~~play ~~emerging~~a ~~growth~~significant ~~companies~~role ~~are~~in ~~exempt~~predicting ~~from:~~and modelling enzyme structures and interactions. Bioinformatics tools analyze vast biological data sets to identify potential target genes and predict enzyme functions.

~~Restrictions on~~Immobilization ~~analyst~~Techniques: Enzymes ~~research~~can ~~prior~~be toimmobilized ~~and~~on ~~immediately~~various ~~after~~supports, ~~the~~enhancing ~~IPO,~~their ~~even~~stability ~~from~~and anreusability. ~~investment~~Immobilization ~~bank~~techniques ~~that~~include isadsorption, ~~underwriting~~covalent ~~the~~binding, ~~IPO;~~and encapsulation.

~~Certain restrictions~~High-Throughput onScreening: Automation ~~communications~~and torobotics ~~institutional~~enable ~~investors~~the ~~before~~screening ~~filing~~of large libraries of enzymes for desired properties, which accelerates the ~~IPO~~identification ~~registration~~of ~~statement;~~enzyme ~~and~~variants with improved characteristics.

~~The requirement~~8 ~~initially~~Table ~~to publicly file IPO Registration Statements. Emerging growth companies can confidentially file draft Registration Statements and any amendments with the SEC. Public filings~~ of ~~the draft documents must be made at least 21 days prior to commencement of the IPO “road show.”~~Contents

~~Other Public~~Synthetic ~~Company~~Biology: Synthetic ~~Requirements~~biology approaches involve designing and constructing new biological components or systems, including enzymes, which allows for the creation of tailor-made enzymes with specific functions.

~~Emerging growth~~Application-Specific ~~companies~~Modifications: Enzyme ~~are~~engineering ~~also~~is ~~exempt~~tailored ~~from~~to ~~other~~the ~~ongoing~~intended ~~obligations~~application, ofwhether ~~most~~it's ~~public~~industrial ~~companies~~processes, ~~such~~biopharmaceutical ~~as:~~production, diagnostics, or environmental applications. Modifications aim to enhance efficiency, specificity, stability, or other desired traits.

~~The requirements~~Enzyme ~~under~~engineering ~~Section~~is ~~14(i)~~a ofmultidisciplinary ~~the~~field ~~Exchange~~that ~~Act~~combines ~~and~~principles ~~Section~~from ~~953(b)(1)~~biochemistry, ofmolecular ~~the~~biology, ~~Dodd-Frank~~protein ~~Act~~engineering, and computational biology to ~~disclose~~modify ~~executive~~and ~~compensation information~~optimize onenzymes ~~pay-~~for~~-performance~~ ~~and~~specific applications. It involves the ~~ratio~~design, creation, and improvement of ~~CEO~~enzymes to ~~median~~enhance ~~employee~~their ~~compensation;~~catalytic activity, stability, specificity, and other properties.

~~Certain other~~Our ~~executive~~current ~~compensation~~efforts ~~disclosure~~in ~~requirements,~~enzyme ~~such~~engineering asfocus ~~the~~on ~~compensation~~establishing ~~discussion~~a solid understanding and ~~analysis,~~developing ~~under~~skills ~~Item~~and ~~402~~resources ofin ~~Regulation S-K;~~several ~~and~~key areas:

~~The requirements~~Computational ~~under~~Approaches: Computational ~~Sections~~methods, ~~14A(a)~~including machine learning, molecular docking, and ~~(b)~~molecular ofdynamics ~~the~~simulations, ~~Exchange~~are ~~Act~~used to ~~hold~~study ~~advisory~~enzyme ~~votes~~structure-function onrelationships, ~~executive~~predict ~~compensation~~enzyme properties, and ~~golden~~guide ~~parachute payments~~the design of improved variants.

~~Smaller Reporting~~Rational ~~Company~~Design: Rational design strategies utilize computational methods, such as molecular modeling and simulation, to predict and engineer enzyme properties. By analyzing enzyme structures and their active sites, researchers can make targeted modifications to enhance catalytic activity, substrate specificity, or stability.

~~We have~~Protein ~~already~~Engineering ~~taken~~Tools: The ~~advantage~~use of ~~these~~novel ~~reduced~~protein ~~reporting~~engineering ~~burdens in this annual report~~tools, ~~which~~such ~~are also available to us~~ as aDNA ~~smaller reporting~~shuffling, ~~company~~site-directed asmutagenesis, ~~defined~~and ~~under Rule 12b~~high-2throughput ofscreening ~~the Securities Exchange Act of 1934~~methods, aswill ~~amended~~accelerate (the ~~“Exchange~~process ~~Act”). Further, we may continue to take advantage~~ of ~~these~~enzyme ~~reduced~~optimization ~~reporting~~and ~~requirements applicable to smaller reporting companies even if we no longer qualify as an “emerging growth company~~discovery.”

~~In addition,~~Directed ~~Section~~Evolution: Directed ~~107~~evolution oftechniques ~~the~~involve ~~JOBS~~generating ~~Act~~genetic ~~also~~diversity ~~provides that an emerging growth company can take advantage of the extended transition period provided~~ in ~~Section~~enzyme ~~7(a)(2)(B)~~libraries ofand ~~the~~screening ~~Securities~~or ~~Act~~selecting ~~of 1933, as amended (the “Securities Act”)~~ for ~~complying~~ variants with ~~new~~improved ~~or revised accounting standards~~properties. WeThis ~~have~~approach ~~elected~~allows us to ~~use~~explore ~~the~~vast ~~extended~~sequence ~~transition~~space ~~period provided above~~ and ~~therefore~~identify ~~our financial~~enzymes ~~statements may not be comparable to companies that comply~~ with ~~public~~desired ~~company effective dates~~traits.

6Enzyme Immobilization: Immobilization techniques involve attaching enzymes to solid supports or matrices, allowing for their reuse and stabilization. Efforts are being made to optimize immobilization methods and explore novel supports to enhance enzyme performance and increase their industrial applicability.

~~WHERE YOU~~It's ~~CAN~~important ~~FIND~~to ~~MORE~~note ~~INFORMATION~~that the field of enzyme engineering is dynamic, and ongoing research continues to expand our understanding of enzyme structure, function, and engineering principles. New discoveries and techniques are continually emerging, shaping the future of enzyme engineering and its applications in various industries. Our effort to gain understanding involves in interaction with experts in the field through conferences, symposia and plan to build academic collaborations to identify novel approaches and convert them into business opportunities.

~~The registrant~~In issummary, ~~subject~~enzyme toengineering ~~the~~combines ~~requirements of the Exchange Act~~genetic, ~~and files reports~~protein, ~~proxy statements~~ and ~~other~~structural ~~information~~engineering with ~~the~~ ~~SEC.~~computational ~~You~~biology ~~may read~~ and ~~copy~~high-throughput ~~these~~screening ~~reports,~~to ~~proxy~~design ~~statements~~ and ~~other~~optimize ~~information~~enzymes atfor ~~the~~specific ~~public reference room maintained by the SEC at its Public Reference Room~~industrial, ~~located at 100 F Street~~medical, ~~N.E.~~or ~~Washington,~~environmental Dapplications.C. ~~20549.~~The ~~You~~field ~~may~~continues ~~obtain information on the operation of the public reference room by calling the SEC at (800) SEC-0330. In addition, we are required~~ to ~~file~~evolve ~~electronic versions of those materials~~ with ~~the~~advancements ~~SEC~~in ~~through the SEC’s EDGAR system. The SEC also maintains a website at http://www.sec.gov~~biotechnology, ~~which~~ ~~contains~~providing ~~reports,~~innovative ~~proxy~~solutions ~~statements~~to ~~and~~various ~~other information regarding registrants that file electronically with the SEC~~challenges.

~~ITEM 1A.~~Quantumzyme ~~RISK~~Current ~~FACTORS~~Properties, Assets & Equipment

~~Smaller reporting~~As ~~companies~~of ~~are~~the date hereof, we do not ~~required~~own any real property. Our office is located in a shared office space which presently is sufficient for our needs, and we pay approximately $500.00 a month. As we continue to ~~provide~~advance our plan of operation, it is our intention to seek larger space to accommodate our needs as necessary. Additionally, the ~~information~~Company ~~required~~currently byhas ~~this~~assets ~~item~~that consist of solely Intellectual Property, Know-How, and previously developed and cultivated relationships that we believe will facilitate our plan of operations as we move forward. Lastly, we do not presently own any equipment as all our research and development activities are conducted at an off-site laboratory that is fully equipped to meet our present needs.

~~ITEM 1B.~~9 ~~UNRESOLVED~~Table ~~STAFF~~of ~~COMMENTS~~Contents

~~Smaller reporting~~Regulatory ~~companies~~and ~~are~~Legal ~~not required to provide the information required by this item.~~Compliance

~~ITEM 2~~Our business operations are subject to various governmental regulations and laws that govern the manufacture, distribution, and use of engineered enzyme products. ~~PROPERTIES~~These regulations are designed to ensure product safety, environmental protection, and workplace health and safety. Key regulatory authorities and legal frameworks applicable to our business include:

~~The Company’s~~1. ~~former~~Environmental ~~principal~~Protection ~~offices~~Agency ~~were~~(EPA): ~~located~~If atour 3engineered ~~Rabi,~~enzymes ~~Rabi,~~involve ~~Czech~~biotechnological ~~Republic~~applications that may impact the environment, ~~34201.~~compliance ~~The~~with ~~property~~the ~~was~~Toxic ~~purchased~~Substances onControl ~~July 30,~~Act ~~2015~~(TSCA) ~~for~~and ~~$11,900~~other EPA regulations is required. ~~The~~2. ~~building~~Occupational ~~was~~Safety ~~impaired~~and Health Administration (OSHA): Governs workplace safety requirements related to the handling, storage, and ~~taken~~manufacturing asof aenzyme-based ~~loss~~products. 3. Other Global Regulatory Bodies: Depending on ~~May~~our 14operational markets, ~~2018~~we asmay aalso ~~result~~comply ofwith ~~the~~similar ~~Change~~regulatory agencies in ~~Control~~Canada (Health Canada), ~~and was~~China ~~recorded~~(National ~~under~~Medical Products Administration), and other ~~expenses~~jurisdictions where we operate.

~~The Company’s~~USA ~~new~~and ~~principal offices are leased in the People’s Republic of China, located at Room 1202, No. 22-2625 Pingliang Road, Yangpu District, Shanghai, China.~~EUROPE

~~ITEM 3.~~Regulations ~~LEGAL~~regarding ~~PROCEEDINGS~~companies that bioengineer enzymes vary depending on the country and the specific nature of the enzymes being produced. However, some common regulatory frameworks to which we may become subject to include:

~~From time~~1. toFood ~~time, we may become involved in various lawsuits~~ and ~~legal~~Drug ~~proceedings~~Administration ~~which~~(FDA) ~~arise~~ in the ~~ordinary~~United ~~course~~States: ofEnzymes ~~business. Litigation~~used ~~is subject to inherent uncertainties, and an adverse result~~ in ~~these~~food orproduction ~~other~~are ~~matters~~subject ~~may arise from time~~ to ~~time~~regulation ~~that may~~by ~~harm our business. To~~ the ~~knowledge of management, no federal, state or local governmental agency is presently contemplating any proceeding against the Company~~FDA. NoThe ~~director,~~FDA ~~executive~~evaluates ~~officer or affiliate of~~ the ~~Company~~safety ~~or owner~~ of ~~record~~these orenzymes ~~beneficially of~~through ~~more~~its ~~than~~Generally ~~five~~Recognized ~~percent~~as ofSafe ~~the~~(GRAS) ~~Company’s~~program. ~~common~~Enzymes ~~stock~~that ishave abeen ~~party~~determined ~~adverse~~ to ~~the~~be ~~Company~~GRAS orcan ~~has~~be aused ~~material~~in ~~interest~~food ~~adverse to~~production ~~the~~without ~~Company~~further inregulatory ~~any proceeding~~oversight.

~~ITEM 4~~2. ~~MINE~~European ~~SAFETY~~Food ~~DISCLOSURES~~Safety Authority (EFSA): In the European Union, enzymes used in food production are regulated by the EFSA. Similar to the FDA's GRAS program, enzymes that are considered safe for use in food are included in the EFSA's list of authorized food enzymes.

~~Not applicable~~3. European Chemicals Agency (ECHA): Enzymes used in industrial processes may be subject to regulation under the Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) regulation in the European Union. This regulation requires companies to register and obtain authorization for the use of certain substances, including enzymes, in industrial applications.

74. Codex Alimentarius Commission: This international food standards organization, jointly run by the Food and Agriculture Organization (FAO) and the World Health Organization (WHO), provides guidelines and recommendations for food safety, including the use of enzymes in food production. While Codex standards are not legally binding, they are often adopted by countries as part of their regulatory frameworks.

~~PART II~~5. Biosafety Regulations: In many countries, including the United States and various European countries, there may be specific regulations governing the use of genetically modified organisms (GMOs) or genetically engineered enzymes. These regulations typically address environmental and health concerns associated with the release of GMOs into the environment or their use in food production.

~~ITEM 5.~~10 ~~MARKET~~Table ~~FOR~~of ~~REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.~~Contents

~~Market for~~UNITED ~~Securities~~ARAB EMIRATES

~~Our common~~Regulations ~~stock~~regarding isbioengineering ~~quoted~~and onenzyme ~~the~~production ~~Over-~~in the ~~Counter~~United ~~Bulletin~~Arab ~~Board~~Emirates (UAE) might not be as extensively documented or publicly available as in some other countries. ToHowever, ~~date~~we ~~there~~believe ~~has~~that ~~been~~the noexisting ~~active~~regulations ~~trading~~and oversight mechanisms in place to ensure the safety of ~~our~~bioengineered ~~common~~products ~~stock.~~and their compliance with international standards are as follows:

~~Holders~~ 1. Ministry of ~~our~~Climate ~~Common~~Change ~~Stock~~and Environment (MOCCAE): The MOCCAE in the UAE is responsible for overseeing environmental regulations and may have a role in regulating bioengineering activities that could impact the environment, such as the release of genetically modified organisms (GMOs) or genetically engineered enzymes into the environment.

~~As of~~2. ~~November~~Biotechnology ~~20,~~Regulatory ~~2018,~~Framework: ~~there~~The ~~were~~UAE 30has ~~registered~~a ~~stockholders,~~regulatory ~~holding~~framework 5specifically addressing biotechnology and genetically modified organisms (GMOs). This framework includes regulations governing the research,~~015~~ development,~~000~~ ~~shares~~production, ofand ~~our~~commercialization ~~issued~~of ~~and~~bioengineered ~~outstanding~~products, ~~common stock~~including enzymes.

~~Dividend Policy~~3. Import and Export Regulations: The UAE has import and export regulations governing the movement of bioengineered products, including enzymes, across its borders. These regulations may include requirements for labeling, documentation, and permits.

~~There are~~4. noInternational ~~restrictions~~Standards inand ~~our~~Agreements: ~~articles~~The ofUAE ~~incorporation~~may oralign ~~bylaws~~its ~~that~~regulations ~~prevent~~with usinternational ~~from~~standards ~~declaring~~and ~~dividends.~~agreements ~~The~~related ~~Nevada~~to ~~Revised~~bioengineering ~~Statutes, however,~~and dobiotechnology. ~~prohibit~~This usalignment ~~from~~could ~~declaring~~include ~~dividends~~adherence ~~where,~~to ~~after~~guidelines ~~giving~~established ~~effect~~by toorganizations such as the ~~distribution~~Codex ofAlimentarius ~~the~~Commission ~~dividend:~~or international treaties addressing biosafety and environmental protection.

	1.	We would not be able to pay our debts as they become due in the usual course of business; or
	2.	Our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

5. Research Ethics and Biosafety: Institutions and companies involved in bioengineering activities in the UAE may be required to adhere to research ethics guidelines and biosafety protocols to ensure the responsible conduct of research and the protection of human health and the environment.

~~We have~~In ~~not~~short, ~~declared~~Management believes that it is essential for any ~~dividends~~company ~~and~~involved wein dobioengineering ~~not~~activities, ~~plan~~including enzyme production, to ~~declare~~consult ~~any~~with ~~dividends~~relevant government agencies and legal experts to ensure compliance with applicable regulations and standards in both the ~~foreseeable~~U.S.A. and the U.A.E. Additionally, regulatory requirements may evolve over time, we intend to stay informed about updates and changes to regulations that may affect our current and future operations.

~~Recent Sales~~Key ofSafety ~~Unregistered Securities~~Considerations

~~On July~~As ~~17,~~a ~~2015,~~company weinvolved ~~issued~~in ~~4,000,000~~the ~~shares~~manufacture of ~~common~~engineered ~~stock~~enzyme toproducts, ~~our~~we ~~previous~~adhere ~~sole~~to ~~officer~~several ~~and~~safety ~~director,~~considerations ~~Stanislav~~to ~~Augustin.~~protect ~~Mr.~~employees, ~~Augustin purchased the 4~~consumers,~~000,000~~ ~~shares~~and atthe ~~a purchase price of $0~~environment.~~001~~ ~~per~~Here ~~share,~~are ~~for~~key ansafety ~~aggregate purchase price of $4,000.~~aspects:

The company’s Registration Statement on Form S-1 was declared effective on October 6, 2016. In October 2016, the company sold 1,015,000 shares of common stock to 31 independent shareholders at a price of $0.04 per share for total proceeds of $40,600, pursuant to the Registration Statement.

	1.	General Workplace Safety

	2.	Occupational Health

~~As reported~~· onPersonal ~~the~~Protective ~~Form~~Equipment ~~8-K~~(PPE): ~~filed~~Employees bymust ~~the~~wear ~~Company~~appropriate ~~with~~PPE ~~the~~(gloves, ~~SEC~~lab oncoats, ~~May 15~~respirators, ~~2018~~etc.) when handling enzyme products, asespecially apowdered ~~result~~or ofaerosolized aforms ~~private~~that ~~transaction,~~may ~~4,000,000~~cause ~~shares of~~respiratory ~~common~~sensitization. ~~stock~~· ofVentilation ~~Reliant~~& ~~were~~Air ~~transferred~~Quality ~~from~~Control: ~~Stanislav~~Adequate ~~Augustin~~air filtration and ventilation systems should be in place to ~~Zhu~~prevent ~~Ming,~~inhalation ~~Wang~~of ~~Ye,~~enzyme Madust ~~Chao,~~and ~~Piao~~aerosols. ~~Guigen,~~· ZuHazard ~~Tianliang, Zhang~~Communication ~~Yulong,~~(HazCom): ~~Yao~~Proper ~~Hongtao,~~labeling ~~Zhu~~and ~~Yukun,~~Safety ~~Chen~~Data ~~Wei,~~Sheets Wu(SDS) ~~Chao,~~must ~~Wang~~be ~~Qinyu,~~maintained ~~Gao~~and ~~Hang,~~provided Geto ~~Shiyang,~~employees Liregarding ~~Shuang,~~enzyme ~~Wang~~handling ~~Mingyu,~~and ~~Cao~~potential ~~Delong, Jin~~hazards. ~~Tong,~~· ~~Wang~~Training ~~Zhiqian,~~& ~~Yang~~Emergency ~~Wanli~~Preparedness: Workers must be trained on safe handling, ~~Zhang~~spill Yeresponse, and ~~Zhu~~emergency ~~Haoyu~~procedures, including first aid measures for accidental exposure.

~~Our company~~11 ~~had~~Table ~~5,015,000 shares~~ of ~~common stock issued and outstanding as of November 20, 2018.~~Contents

~~Purchases of~~3. ~~Equity~~Product ~~Securities~~Safety by& ~~the~~Consumer ~~Issuer and Affiliated Purchasers~~Protection

~~None~~· GRAS (Generally Recognized as Safe) Compliance: If enzymes are used in food, they must comply with FDA or equivalent international GRAS standards. · Allergen & Toxicity Testing: Companies must conduct rigorous testing to ensure that enzyme products do not pose allergenic, toxic, or other health risks. · Purity & Contamination Control: Manufacturing processes must prevent microbial or chemical contamination to ensure product safety and integrity.

~~Securities Authorized~~4. ~~for~~Environmental ~~Issuance~~Safety ~~Under~~& ~~Equity~~Waste ~~Compensation Plans~~Management

~~None~~· Biodegradability & Environmental Impact Assessments: Companies must assess the potential impact of engineered enzymes on ecosystems, including biodegradability and persistence in the environment. · Waste Disposal Compliance: Enzyme waste, byproducts, and expired materials must be disposed of according to hazardous waste regulations (e.g., EPA’s Resource Conservation and Recovery Act, EU Waste Framework Directive). · Spill Prevention & Containment: Protocols should be in place to prevent accidental releases, including secondary containment systems and spill response plans.

85. Biosecurity & Genetic Engineering Compliance

~~ITEM 6~~· Biosafety Levels (BSL): If working with genetically modified enzymes, facilities must comply with appropriate biosafety level classifications (BSL-1 to BSL-3) depending on risk factors. ~~SELECTED~~· ~~FINANCIAL~~Gene ~~DATA~~Editing & GMO Regulations: Compliance with laws such as the USDA’s Biotechnology Regulations, the Cartagena Protocol on Biosafety, and EU GMO Directives is required when modifying organisms for enzyme production. · Containment & Cross-Contamination Prevention: Procedures should be in place to prevent unintended release of genetically engineered microorganisms or enzymes.

~~Smaller reporting~~6. ~~companies~~Fire ~~are~~& ~~not~~Chemical ~~required to provide the information required by this item.~~Safety

~~ITEM 7~~· Flammability & Chemical Handling: Some enzymes may require careful handling due to their reaction with other chemicals or potential combustion risk. ~~MANAGEMENT’S~~Compliance ~~DISCUSSION~~with ~~AND~~NFPA ~~ANALYSIS~~(National OFFire ~~FINANCIAL~~Protection ~~CONDITION~~Association) ~~AND~~standards. ~~RESULTS~~· OFStorage ~~OPERATIONS~~& Labeling: Enzymes and related chemicals must be stored safely, with clear hazard identification and adherence to local and international chemical safety regulations (e.g., OSHA’s Hazard Communication Standard, GHS labeling).

~~Overview~~Our Competition.

The ~~following~~ ~~financial~~bioengineering ~~data~~of ~~was~~enzymes ~~extracted~~sector ~~from~~encompasses ~~the~~a ~~audited~~wide ~~financial~~range ~~statements~~ of ~~Reliant~~players, ~~Service~~including ~~Inc~~companies, research institutions, and academic organizations. ~~for~~As we are in the ~~years~~initial ~~ended~~rollout ~~July 31~~of our plan of operation, ~~2018~~we believe that the major players in our industry will generally be better funded and ~~2017~~will have the ability to attract and hire qualified candidates in all facets of our business. The following is an overview of the key players in this field:

~~This report~~Biotech: ~~contains~~Numerous ~~forward-looking~~biotechnology ~~statements~~companies ~~which~~specialize ~~relate to future events or our future financial performance. While these forward-looking statements, and any assumptions upon which they are based, are made~~ in ~~good faith and reflect our current judgment regarding~~ the ~~direction~~ bioengineering of ~~our~~enzymes ~~business,~~for ~~actual~~various ~~results~~industrial ~~may differ materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein~~applications. ~~Expect~~These ascompanies ~~required~~often bydevelop ~~applicable~~proprietary ~~law,~~technologies ~~including~~and ~~the~~enzyme ~~securities~~products ~~laws~~tailored ~~of the United States, we do not intend~~ to ~~update~~specific ~~any~~industrial ofprocesses. ~~the~~Some ~~forward-looking~~prominent ~~statements~~players ~~to conform these statements to actual results.~~include:

~~Results~~ · Novozymes: One of ~~Operation~~the largest and most well-known enzyme manufacturers globally, offering enzymes for applications in industries such as agriculture, bioenergy, food and beverages, household care, and more. · DuPont Industrial Biosciences: Known for its expertise in enzyme production and bio-based solutions for industries like food and beverage, animal nutrition, textiles, and biofuels. · BASF: Offers a wide range of enzyme products for applications in detergents, food processing, animal nutrition, and more. · Codexis: Specializes in enzyme engineering for pharmaceuticals, biofuels, and industrial chemicals. · Genencor: Known for its innovations in enzyme technology for various industrial applications, including biofuels, textiles, and detergents.

~~Comparison of~~12 ~~Years~~Table ~~Ended~~of ~~July 31, 2018 and 2017~~Contents

~~The following~~Research ~~table~~Institutions ~~sets~~and ~~forth~~Universities: ~~key~~Academic ~~components~~institutions ofplay ~~our~~a ~~results~~crucial ofrole ~~operations~~in ~~during~~advancing the ~~year~~field ~~ended~~of ~~July~~enzyme 31bioengineering through fundamental research and technology development. Some notable institutions with active research programs in this area include MIT, ~~2018~~Harvard University, University of California, Berkeley, ETH Zurich, and ~~2017~~the University of Cambridge.

	Year ended July 31, 2018			Year ended July 31, 2017			Change
Revenues	$	93,550		$	128,147		$	(34,597	)
Cost of sales		89,345			105,847			(16,502	)
Gross profit		4,205			22,300			(18,095	)
Operating expenses		17,121			60,957			(43,836	)
Total expenses		17,121			60,957			(43,836	)
Total other income/(expenses)		(15,251	)		-			(15,251	)
Loss before tax		(28,167	)		(38,657	)		10,490
Income tax benefit(provision)		-			5,799			(5,799	)
Net loss	$	(28,167	)	$	(32,858	)	$	4,691

Government Agencies and Funding Bodies: Government agencies and funding bodies provide support for research and development in enzyme bioengineering through grants, funding programs, and regulatory oversight. Examples include the National Institutes of Health (NIH) in the United States, the European Commission's Horizon 2020 program, and various national research councils.

9Contract Research Organizations (CROs): Contract research organizations provide services related to enzyme bioengineering, including enzyme discovery, optimization, and production. These organizations collaborate with industry partners to develop custom enzyme solutions for specific applications.

~~We generated~~While ~~$93~~we believe that our methods,~~550~~ approach, and ~~$128,147~~plan inof ~~revenues~~operation ~~for~~will ~~the~~allow ~~years~~us ~~ended~~to ~~July~~offer 31similar services at competitive pricing, ~~2018~~we ~~and~~are ~~2017~~aware ~~respectively.~~that ~~Our~~competitors ~~cost~~are oflikely ~~sales~~in ~~was~~a ~~$89~~position to dedicate vast resources,~~345~~ in both research and ~~$105~~development,~~847~~ ~~resulting~~and in enzyme engineering that we may be put at a ~~gross~~significant ~~profit~~disadvantage ofin $4landing large customer accounts. However,~~205~~ as we intend to keep operations minimal and ~~$22~~offer extremely competitive solutions,~~300~~ ~~respectively~~while offering access to our entire team as we grow, we believe our success will be in our dedication to our business and scientific principals which will be our key differentiator as we ramp up operations.

~~The operating~~Understanding ~~expenses for~~ the ~~years~~landscape ~~ended~~of ~~July~~industry ~~31,~~players ~~2018~~in ~~and~~the ~~2017~~bioengineering ~~were $17,121 and $60,957 respectively. These expenses mainly consisted~~ of ~~professional~~enzymes ~~fees,~~sector ~~depreciation~~involves ~~and~~recognizing ~~bank~~the ~~charges.~~diverse ~~The~~range ~~decrease~~ of ~~operating~~organizations ~~expenses~~contributing into ~~the~~research, ~~year~~development, ~~2018~~production, ~~was~~and ~~mainly~~commercialization ~~due~~efforts ~~to the decrease~~ in ~~professional~~this ~~fees~~field.

~~Liquidity and~~Scientific ~~Capital~~Advisory ~~Resources~~Board

	July 31, 2018			July 31, 2017
Working capital
Total current assets	$	-		$	7,448
Total current liabilities		8,524			100
Working capital surplus/(deficiency)	$	(8,524	)	$	7,348

While our management has extensive experience in both corporate management and business operations, they also have experience in the pursuit of various scientific endeavors(see Management’s Biographies below). In addition to their personal experience, they will set up a Scientific Advisory Board to continue to move the Company’s pursuit of engineering novel enzymes forward. The goal is to set up a Scientific Advisory Board with accomplished scientists in the fields of Chemical and Biochemical Engineering and Chemistry.

~~As of July 31, 2018, we had cash and cash equivalents of $nil. To date, we have financed our operations primarily through contributions by owners.~~Employees

~~The following~~We ~~table~~have ~~provides~~one ~~detailed~~employee ~~information~~which ~~about~~is our ~~net~~President ~~cash~~and ~~flows~~member ~~for~~of the ~~year~~Company’s ~~ended~~Board ~~July~~of 31Directors, ~~2018~~Mr. ~~and~~Kulkarni. ~~2017~~Currently, Mr. Kulkarni has the flexibility to work on our business up to 40 hours per week but is prepared to devote more time if necessary. We do not presently have pension, health, annuity, insurance, stock options, profit sharing, or similar benefit plans; however, we may adopt plans in ~~this~~the ~~report:~~future.

~~Cash Flow~~There are presently no personal benefits available to our employee, Officer and/or Director.

	2018			2017
Net cash provided by (used in) operating activities	$	(2,744	)	$	(38,077	)
Net cash provided by (used in) investing activities		-			-
Net cash provided by (used in) financing activities		-			40,600
Net increase (decrease) in cash and cash equivalents		(2,744	)		2,523
Cash and cash equivalents at beginning of period		2,744			221
Cash and cash equivalents at end of period	$	-		$	2,744

CORPORATE HISTORY

10Quantumzyme Corp. was incorporated in the State of Nevada on March 20, 2015, originally under the name Reliant Service Inc.

~~Operating Activities~~In April 2023, the Company changed its corporate name to Quantumzyme Corp. and its trading symbol to QTZM following the acquisition of assets from Quantumzyme Inc., a Delaware corporation.

~~Net cash~~13 ~~used~~Table ~~in operating activities was $2,744 for the year ended July 31, 2018, as compared to that~~ of $38,077 for the year ended July 31, 2017. The decrease in net cash used in operating activities was mainly due to loss of impairment of assets, decrease in income tax benefit and the increase in accounts payable and accrued liabilities.Contents

~~Investing Activities~~Pursuant to that Asset Purchase Agreement, Quantumzyme Corp. acquired proprietary enzyme-engineering technology focused on clean and green chemistry applications that enhance enzyme activity, selectivity, and specificity through quantum mechanics and molecular modeling. In exchange, the Company issued 150 million restricted shares of common stock to Mr. Naveen Krishnarao Kulkarni, who became the Company’s Chief Executive Officer and controlling shareholder.

~~Net cash~~Quantumzyme ~~used~~Corp. inis ~~investing~~an ~~activities~~early-stage, ~~for~~emerging ~~the~~growth ~~years~~company ~~ended~~headquartered ~~July~~in 31San Diego, ~~2018~~California, engaged in the research, development, and ~~2017~~planned ~~was~~commercialization ~~both~~of ~~$nil~~engineered enzymes for use in biotransformation and sustainable chemical manufacturing.

~~Financing Activities~~Our principal executive office is located at 15656 Bernardo Center Drive, Suite 801, San Diego, CA 92127, and our telephone number is (858) 203-0312. Additional information is available at www.quantumzymecorp.com (the website is not incorporated by reference into this report).

~~Net cash~~The ~~provided~~Company byis ~~financing~~currently ~~for~~in the ~~year~~development ~~ended~~stage ~~July~~and ~~31,~~has ~~2018~~not ~~was~~yet ~~$nil,~~generated asrevenue. ~~compared~~Future tooperations ~~$40,600~~will ~~for~~depend on the ~~year~~successful ~~ended~~execution ~~July~~of ~~31,~~its ~~2017. The~~business ~~decrease~~plan ofand ~~net~~the ~~cash~~ability ~~provided~~to byobtain additional financing. ~~activities~~Given ~~was~~its ~~because~~limited weoperating ~~did~~history, ~~not~~investors ~~have~~should ~~any~~consider ~~financing~~the ~~activities~~Company’s business and prospects as highly speculative.

~~Contractual Obligations~~AVAILABLE ~~and Commercial Commitments~~INFORMATION

~~Debt~~The Company prepares and files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and certain other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov.

~~On April~~ITEM ~~14, 2015, the former director and president of the Company, made the initial deposit to the Company bank account in the amount $100 and was carried as a loan payable~~1A. ~~The~~RISK ~~loan was non-interest bearing, unsecured and due upon demand~~FACTORS. ~~The loan was assumed by the former shareholder on May 14, 2018 as result of change in control. The assumption is recorded as part of the impairment of assets.~~

~~On July~~RISK 10, 2018, the current director and president of the Company paid on behalf of the company certain expenses during the transition period of changing control. The current director waived such payables due to him and the Company recorded such waiver as an addition to additional paid in capital.FACTORS

~~Related party~~Please ~~transactions~~consider the following risk factors and other information in this Registration Statement relating to our business and prospects before deciding to invest in our Shares. This Registration Statement and any investment in our Shares involve a high degree of risk. You should carefully consider the risks described below and all of the information contained in this Registration Statement before deciding whether to purchase our Shares. If any of the following risks actually occur, our business, financial condition and results of operations could be harmed, and you may lose all or part of your investment. The Company should be viewed as a high-risk investment and speculative in nature. An investment in our Shares may result in a complete loss of the invested amount. Please consider the following risk factors before deciding to invest in our Shares.

~~On April~~Financial ~~14, 2015 the Director and President of the Company made the initial deposit to the Company bank account in the amount $100~~Projections. The loan is non-interest bearing, unsecured and due upon demand. The loan was assumed by the former shareholder on May 14, 2018 as result of change in control. The assumption is taken as an addition to additional paid in capital.

~~On July~~Any ~~17,~~financial ~~2015,~~projections ~~4,000,000~~are ~~shares~~based ofupon what the Company’s ~~common~~believes ~~stock~~to ~~were~~be ~~issued~~reasonable toassumptions ~~our~~concerning ~~sole~~certain ~~director~~factors ~~for~~affecting ~~$4,000.~~probable ~~The~~future operations of the Company~~’s sole~~. ~~officer~~Despite ~~and~~these ~~director~~future isprojections, ~~involved~~no inassurances ~~other~~can ~~business~~be ~~activities~~made ~~and~~that ~~may~~these inprojections ~~the~~will ~~future~~prove to be accurate, ~~become~~and ~~involved~~potential investors are cautioned against placing excessive reliance on such projections in ~~other~~deciding ~~business~~whether ~~opportunities as~~to ~~they~~invest ~~become~~in ~~available~~the Company.

~~On July~~We ~~10,~~may ~~2018,~~fail ~~the current director and president of the Company paid on behalf of the company certain expenses during the transition period of changing control. The current director waived such payables due~~ to ~~him~~establish and ~~the~~maintain ~~Company~~strategic ~~recorded such waiver as an addition to additional paid in capital~~relationships.

We believe that ~~our~~the ~~current~~establishment ~~cash~~of ~~and~~strategic ~~financing~~partnerships ~~from~~will ~~our~~greatly ~~existing~~benefit ~~stockholders are adequate to support operations for at least~~ the ~~next~~ 12growth ~~months. We may, however, in the future, require additional cash resources due to changing business conditions, implementation~~ of our ~~strategy to expand our~~ business, orand ~~other investments or acquisitions~~ we ~~may~~intend ~~decide~~ to ~~pursue. If our own financial resources are insufficient to satisfy our capital requirements, we may~~ seek toout ~~sell~~and ~~additional~~enter ~~equity~~into orstrategic ~~debt securities or obtain additional credit facilities~~alliances. ~~The~~We ~~sale~~may ofnot ~~additional~~be ~~equity~~able ~~securities could result in dilution~~ to ~~our~~enter ~~stockholders.~~these ~~The~~strategic ~~incurrence~~partnerships ofon ~~indebtedness would~~commercially ~~result~~reasonable interms, ~~increased~~or ~~debt~~at ~~service~~all. ~~obligations~~Even ~~and~~if ~~could~~we ~~require~~enter usstrategic toalliances, ~~agree to operating and financial covenants that would restrict~~ our ~~operations.~~partners ~~Financing~~ may not beattract ~~available~~significant innumbers ~~amounts~~of clients or onotherwise ~~terms~~prove ~~acceptable~~advantageous to ~~us,~~our ~~if at all~~business. ~~Any~~Our ~~failure~~inability ~~by us~~ to ~~raise~~enter ~~additional~~new ~~funds~~strategic onalliances ~~terms favorable to us, or at all,~~ could ~~limit~~have ~~our~~a ~~ability~~material toand ~~expand~~adverse ~~our~~effect ~~business~~on ~~operations and could harm~~ our ~~overall~~ business ~~prospects~~.

1114 Table of Contents

~~Capital Expenditures~~If we were to lose the services of Mr. Kulkarni, we may not be able to execute our business strategy.

~~Capital expenditures~~We ~~for~~currently depend on the ~~years~~continued ~~ended~~services ~~July~~and 31performance of the key member of our management team, ~~2018~~comprised solely of Mr. Kulkarni. His leadership has played an integral role in our company. The loss of the key member of our management team could disrupt our operations and ~~2017~~have ~~were~~an ~~both~~adverse ~~$nil~~effect on our ability to grow our business. WeIn doaddition, ~~not~~competition ~~anticipate~~for ~~any~~senior ~~capital~~executives ~~expenditures~~and key personnel in ~~the~~our ~~next financial~~industry ~~year~~is ~~ended~~intense, ~~July~~and 31we may be unable to retain our senior executives and key personnel or attract and retain new senior executives and key personnel in the future, ~~2019~~in which case our business may be severely disrupted.

~~Inflation~~If we are unable to hire qualified personnel and retain or motivate key personnel, we may not be able to grow effectively.

~~Inflation and~~Our ~~changing~~future ~~prices~~success ~~have~~depends ~~not~~on ~~had~~our acontinuing ~~material~~ability ~~effect~~to onidentify, ~~our~~hire, ~~business~~develop, motivate, and weretain doskilled ~~not~~personnel ~~expect~~for ~~that~~all ~~inflation~~areas orof ~~changing~~our ~~prices~~organization. ~~will materially~~Competition ~~affect~~in our ~~business~~industry infor ~~the~~qualified ~~foreseeable~~employees ~~future.~~is ~~However,~~very ~~our~~competitive. ~~management~~Our ~~will~~continued ~~closely~~ability ~~monitor~~to ~~price~~compete ~~changes~~effectively independs on our ~~industry~~ ability to attract new employees and ~~continually~~to ~~maintain~~retain ~~effective~~and ~~cost~~motivate ~~control~~our inexisting ~~operations~~employee.

~~Off Balance~~Our ~~Sheet~~Limited ~~Arrangements~~Workforce May Hinder Our Ability to Execute Our Business Objectives

~~We do~~As ~~not~~of the date of this filing, we have ~~any~~only ~~off~~one ~~balance~~employee, ~~sheet~~our ~~arrangements~~ability ~~that~~to ~~have~~achieve orour ~~are~~business ~~reasonably~~objectives ~~likely~~depends on the efforts and capabilities of this sole employee, who is responsible for overseeing all aspects of our operations. The absence of additional employees may limit our capacity to ~~have~~effectively amanage ~~current~~product development, regulatory compliance, business development, and other critical functions. While we engage independent contractors or ~~future~~consultants ~~effect~~to onsupport our ~~financial condition~~operations, ~~changes~~there inis ~~financial~~no ~~condition~~guarantee that we will be able to secure qualified personnel on favorable terms. Additionally, ~~revenues~~reliance oron ~~expenses~~a single employee increases our exposure to risks associated with workload constraints, ~~results~~potential turnover, and the loss of ~~operations,~~key ~~liquidity~~knowledge or ~~capital~~expertise. ~~expenditures~~While orwe ~~capital resources~~do ~~that~~not isanticipate ~~material~~difficulties toin anacquiring ~~investor~~qualified employees as needed in the future, if we are unable to expand our ~~securities~~workforce as needed, our ability to execute our business plan, meet key milestones, and achieve commercial success could be adversely affected.

~~Seasonality~~A decline in general economic conditions could have a material adverse effect on our business, financial condition, and results of operations.

Our operating ~~results~~ and ~~operating~~financial ~~cash~~performance ~~flows~~may ~~historically~~be ~~have~~adversely ~~not~~affected ~~been~~by ~~subject~~a tovariety ~~significant~~of ~~seasonal~~factors ~~variations~~that influence the general economy. ~~This~~It ~~pattern may~~is ~~change,~~our ~~however,~~opinion asthat ain ~~result~~the event of ~~new~~an ~~market~~economic ~~opportunities~~slowdown, spending habits of both consumers and businesses could be adversely affected and we could experience lower net sales than expected on a quarterly or ~~new~~annual ~~product~~basis ~~introductions~~which could have a material adverse effect on our business, financial condition, and results of operations.

~~Critical Accounting~~Our ~~Policies~~sole officer and director have little experience managing a public company.

~~The preparation~~Mr. ofKulkarni, ~~financial~~our ~~statements~~sole inofficer, ~~conformity~~and ~~with~~director ~~accounting~~has ~~principles~~limited ~~generally~~experience ~~accepted~~managing ina ~~the~~public ~~United~~company ~~States~~which ~~requires our~~is ~~management~~required to ~~make~~establish ~~assumptions, estimates~~ and ~~judgments~~maintain ~~that~~disclosure ~~affect~~controls ~~the~~and ~~amounts~~procedures ~~reported, including the notes thereto,~~ and ~~related~~ ~~disclosures~~internal ofcontrol ~~commitments~~over ~~and~~financial ~~contingencies, if any~~reporting. WeAs ~~have~~a ~~identified~~result, ~~certain~~we ~~accounting~~may ~~policies~~not ~~that~~be ~~are~~able ~~significant~~ to ~~the~~operate ~~preparation~~successfully ofas ~~our~~a ~~financial~~public ~~statements.~~company, ~~These~~even ~~accounting~~if ~~policies are important for an understanding of~~ our ~~financial condition~~operations ~~and~~are ~~results of operation~~successful. ~~Critical~~We ~~accounting~~plan ~~policies~~to ~~are~~comply ~~those~~with ~~that~~all ~~are~~of ~~most important to~~ the ~~portrayal~~various ofrules ~~our financial condition~~ and ~~results of operations and require management’s difficult~~regulations, ~~subjective,~~which orare ~~complex~~required ~~judgment,~~for ~~often as~~ a ~~result of~~public ~~the~~company ~~need~~that tois ~~make~~reporting ~~estimates~~company ~~about~~with the ~~effect~~Securities ~~of matters that are inherently uncertain~~ and ~~may~~Exchange ~~change in subsequent periods~~Commission. ~~Certain~~ ~~accounting~~However, ~~estimates~~if ~~are~~we ~~particularly~~cannot ~~sensitive~~operate ~~because~~successfully ofas ~~their~~a ~~significance~~public tocompany, ~~financial~~your ~~statements~~investment ~~and because of the possibility that future events affecting the estimate~~ may ~~differ~~be ~~significantly~~materially ~~from~~adversely ~~management’s current judgments~~affected. ~~We believe the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our financial statements:~~

~~Method of~~We ~~accounting~~may need additional capital in the future in order to expand our business.

~~Management has~~Our ~~prepared~~future capital requirements may be substantial, particularly as we continue to develop our business. Although we believe that, based on our current level of operations, our existing cash, cash equivalents and equity securities will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the ~~accompanying~~next 12 months, we may need additional capital if our current plans and assumptions change. Our need for additional capital will depend on many factors, including the financial ~~statements~~success of our performance enzyme business, our spending to develop and ~~these~~commercialize ~~notes~~new inand ~~accordance~~existing products and the amount of collaboration funding we may receive to ~~generally~~help ~~accepted~~cover ~~accounting~~the ~~principles~~cost in of such expenditures, the ~~United~~effect ~~States~~of any acquisitions of ~~America;~~other businesses, technologies or facilities that we may make or develop in the ~~Company~~future, ~~maintains~~our ~~its~~spending ~~general~~on ~~ledger~~new market opportunities, and ~~journals~~the filing, prosecution, enforcement, and defense of patent claims. If our capital resources are insufficient to meet our capital requirements, and we are unable to enter into or maintain collaborations with partners that are able or willing to fund our development efforts or commercialize any products that we develop or enable, we will have to raise additional funds to continue the ~~accrual~~development ~~method~~of ~~accounting~~our technology and products and complete the commercialization of products, if any, resulting from our technologies.

1215 Table of Contents

~~Use~~ In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. We may seek to obtain such additional capital through equity offerings, debt financings, credit facilities and/or strategic collaborations. If future financings involve the issuance of ~~estimates~~equity securities, our existing stockholders will suffer dilution. If we raise debt financing or enter into credit facilities, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and fail to generate sufficient revenues to achieve planned gross margins and to control operating costs, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.

~~The preparation~~With ofrespect ~~financial~~to ~~statements~~customers inpurchasing ~~conformity~~our ~~with~~products ~~generally~~for ~~accepted~~the ~~accounting~~manufacture ~~principles~~of ~~requires~~active ~~management~~pharmaceutical ingredients (“API”) for which they have exclusivity due to ~~make~~patent ~~estimates~~ protection, the termination or expiration of such patent protection and ~~assumptions~~any ~~that~~resulting ~~affect~~generic ~~certain~~competition ~~reported~~may ~~amounts~~materially and ~~disclosures.~~adversely ~~Accordingly,~~affect ~~actual~~our ~~results~~revenues, ~~could~~financial ~~differ~~condition, ~~from~~or ~~those~~results ~~estimates~~of operations.

~~Revenue recognition~~With respect to customers purchasing our products for the manufacture of API, or lead to the manufacture of API, for which exclusivity due to patent protection has or is about to expire, we can expect that the quantity of our products sold to such customers for such products may decline as generic competition for the API increases. While we anticipate that we may, in some cases, also be able to sell products to these generic competitors for the manufacture of these APIs, or lead to the manufacture of these APIs, the overall effect on our revenues, financial condition and results of operations could be materially adverse.

~~The Company~~We ~~recognizes~~are ~~revenues~~dependent ~~and~~on ~~the~~a ~~related~~limited ~~costs~~number ~~when persuasive evidence~~ of ancontract ~~arrangement~~manufacturers ~~exists,~~for ~~delivery~~large ~~and~~scale ~~acceptance~~production ~~has occurred, the price is fixed or determinable, and collection~~ of ~~any~~substantially ~~resulting~~all ~~receivable is reasonably assured. Costs and expenses are recognized during the period in which they are incurred. Any revenues earned are from the sales~~ of ~~office~~our ~~equipment~~enzymes. ~~The Company recognizes these sales once delivery time is confirmed by the customer.~~

~~All revenue~~We ~~generated~~have limited internal capacity to manufacture enzymes. As a result, we are dependent upon the performance and capacity of third-party manufacturers for the larger scale manufacturing of the enzymes used in our business. Accordingly, we face risks of difficulties with, and interruptions in, performance by third party manufacturers, the ~~Company~~occurrence toof ~~date~~which ~~has~~could ~~been~~adversely ~~generated~~impact ~~from~~the Uavailability, launch and/or sales of our enzymes in the future.S Enzyme manufacturing capacity limitations at our third-party manufacturers and manufacturing delays could negatively affect our business, reputation, results of operations and financial condition. ~~sales~~We may be forced to secure alternative sources of supply, which may be unavailable on commercially acceptable terms, and ~~deposited~~could cause delays in our ability to deliver products to our ~~U.S.~~customers, ~~bank~~increase ~~account~~our costs and decrease our profit margins.

~~Recent Accounting~~The ~~Pronouncements~~Lack of Formal Agreements for Off-Site Testing Facilities May Disrupt Our Operations and Increase Costs

~~Management has~~We ~~considered~~rely ~~all~~on ~~recent~~third-party ~~accounting~~testing ~~pronouncements~~facilities, ~~issued~~which ~~since~~we ~~the~~use ~~last~~on ~~audit~~an ofas-needed ~~our~~basis ~~financial~~without ~~statements~~formal written agreements. The ~~Company’s management~~absence ~~believes~~of ~~that~~binding agreements poses several risks, including potential limitations on facility availability, increased costs, and disruptions to our testing schedule. If these ~~recent~~facilities ~~pronouncements~~become ~~will~~unavailable ~~not~~or ~~have~~impose aunfavorable ~~material~~terms, ~~effect~~we onmay experience delays in product development, increased expenses, or the ~~Company’s~~need ~~financial~~to ~~statements~~secure alternative facilities, which could be costly and time-consuming. Any such disruptions could adversely affect our ability to advance our products and achieve commercialization in a timely manner.

~~ITEM 7A.~~16 ~~QUANTITATIVE~~Table ~~AND~~of ~~QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~Contents

~~Not applicable~~Competitors and potential competitors who have greater resources and experience than we do may develop products and technologies that make ours obsolete or may use their greater resources to again ~~smaller~~market ~~reporting~~share ~~company~~at our expense.

~~ITEM 8~~Our future success will depend on our ability to maintain a competitive position with respect to technological advances. ~~FINANCIAL~~In ~~STATEMENTS~~addition, ~~AND~~as ~~SUPPLEMENTARY~~we ~~DATA~~enter new markets, we will face new competition and will need to adapt to competitive factors that may be different from those we face today. Our primary competitors in the performance enzymes for pharmaceutical products are companies marketing either conventional, non-enzymatic processes or biocatalytic enzymes to manufacturers of pharmaceutical intermediates and APIs, and also existing in-house technologies (both biocatalysts and conventional catalysts) within our client and potential client companies. The principal methods of competition and competitive differentiation in this market are price, product quality and performance, including manufacturing yield, safety and environmental benefits, and speed of delivery of product. Additionally, the market for the manufacture and supply of APIs is large with many established companies.

~~The consolidated~~Ultimately, ~~financial~~our ~~statements~~ability to compete successfully in any of these markets will depend on our ability to develop proprietary products that reach the ~~Company~~market in a timely manner and are ~~included~~technologically insuperior ~~this~~to ~~Annual~~and/or ~~Report~~are onless ~~Form~~expensive ~~10-K~~than ~~beginning~~other products on ~~page~~the ~~F-1~~market. Many of our competitors have substantially greater production, financial, research and development, personnel, and marketing resources than we do. They also started developing products earlier than we did, which ~~are~~ ~~incorporated~~may ~~herein~~allow bythem ~~reference~~to establish blocking intellectual property positions or bring products to market before we can.

~~ITEM 9~~Our competitors may be able to develop competing and/or superior technologies and processes and compete more aggressively and sustain that competition over a longer period of time than we could. ~~CHANGES~~Our INtechnologies ~~AND~~and ~~DISAGREEMENTS~~products ~~WITH~~may ~~ACCOUNTANTS~~be ONrendered ~~ACCOUNTING~~obsolete ~~AND~~or ~~FINANCIAL~~uneconomical ~~DISCLOSURE~~by technological advances or entirely different approaches developed by one or more of our competitors. We cannot be certain that any products we develop in the future will compare favorably to products offered by our competitors or that our existing or future products will compare favorably to any new products that are developed by our competitors. As more companies develop new intellectual property in our markets, the possibility of a competitor acquiring patent or other rights that may limit our products or potential products increases, which could lead to litigation.

~~None~~Our limited resources relative to many of our competitors may cause us to fail to anticipate or respond adequately to new developments and other competitive pressures. This failure could reduce our competitiveness and market share, adversely affect our results of operations and financial position, and prevent us from obtaining or maintaining profitability.

13Ethical, legal, and social concerns about genetically engineered products and processes could limit or prevent the use of our technology, products and processes and limit our revenues.

~~ITEM 9A~~We anticipate that some of our future technology, products, and services may be genetically engineered or involve the use of genetically engineered products or genetic engineering technologies. ~~CONTROLS~~If ~~AND~~we ~~PROCEDURES~~and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, our technology, products, and services may not be accepted. Any of the risks discussed below could result in increased expenses, delays, or other impediments to our programs or the public acceptance and commercialization of products and processes dependent on our technologies or inventions.

~~Evaluation of~~Our ~~disclosure~~efforts ~~controls~~to prosecute, maintain, protect and/or ~~procedures~~defend our intellectual property rights may not be successful.

~~We are~~As ~~required~~of tothe ~~maintain~~date ~~disclosure~~of ~~controls~~this report, we have not filed for patent protection for our product and ~~procedures~~do ~~that~~not ~~are~~anticipate ~~designed~~doing toso ~~ensure~~in the near future. At this time, the costs associated with patent prosecution outweigh the anticipated benefits. However, we anticipate that ~~information~~we ~~required~~will file and prosecute patent applications and endeavor to bemaintain ~~disclosed~~ trade secrets in an ongoing effort to protect our ~~reports~~intellectual ~~filed~~property ~~under~~rights as we move the ~~Securities~~business ~~Exchange~~forward. ~~Act~~It ofis ~~1934~~possible that our future patents, asor ~~amended~~patents which we may later acquire, may be successfully challenged, or invalidated, in whole or in part. It is ~~recorded~~also possible that we may not obtain issued patents from our pending patent applications. Accordingly, ~~processed~~and due to uncertainties inherent in prosecuting patent applications, ~~summarized~~sometimes patent applications are rejected, and ~~reported~~we ~~within the~~subsequently ~~time~~abandon ~~periods~~them. ~~specified~~It is also possible that we may develop proprietary technology, products or services in the ~~Securities~~future ~~and~~that ~~Exchange~~are ~~Commission’s~~not ~~rules~~patentable ~~and~~or ~~forms~~that the patents of others will limit or altogether preclude our ability to conduct business. In addition, ~~and~~any ~~that~~patent issued to us or to our licensor may provide us with little or no competitive advantage, in which case we may abandon such ~~information~~patent isor ~~accumulated and~~license ~~communicated~~it to ~~our~~another ~~management~~entity or terminate the license agreement. Additionally, ~~including~~litigation may be necessary to enforce our ~~chief~~intellectual ~~executive~~property ~~officer~~rights, ~~(also~~to protect our ~~principal~~trade ~~executive~~secrets, ~~officer)~~to determine the validity and ~~our~~scope ~~chief financial~~of ~~officer~~the ~~(also~~proprietary ~~our~~rights ~~principal~~of ~~financial~~others, or to defend against claims of infringement, invalidity, misappropriation, or other claims. Any such litigation could result in substantial costs and ~~accounting~~diversion ~~officer)~~of our resources. Moreover, any settlement of or adverse judgment resulting from litigation relating to ~~allow~~intellectual property rights could require us to obtain a license to continue to make, use, import, sell or offer for ~~timely~~sale ~~decisions~~the ~~regarding~~technology, ~~required~~products ~~disclosure~~or services that is the subject of the claim, or otherwise restrict or prohibit our use of the technology, products, or services.

~~Pursuant to~~17 ~~Rule~~Table ~~13a-15(b) under the Securities Exchange Act~~ of 1934 (“Exchange Act”), the Company’s management, including the Company’s Chief Executive Officer (“CEO”) (the Company’s principal executive officer) and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures were not effective as of July 31, 2018 to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. The principal basis for this conclusion is the lack of segregation of duties within our financial function and the lack of an operating Audit Committee.Contents

~~Management’s Report~~Third onparties ~~Internal~~may ~~Control~~claim ~~over~~that ~~Financial~~we ~~Reporting~~are infringing, violating, or misappropriating their intellectual property rights, which may subject us to costly and time-consuming litigation and prevent us from developing or commercializing our technology, products, or services.

~~Management is~~Our ~~responsible~~commercial ~~for~~success ~~establishing~~also ~~and~~depends ~~maintaining~~in ~~adequate~~part ~~internal~~on ~~control~~our ~~over~~ability ~~financial~~to ~~reporting~~operate ~~(as~~without ~~defined~~infringing, inviolating ~~Exchange~~or ~~Act Rule~~misappropriating ~~13a-15(f)).~~patents ~~The~~and ~~Company’s~~other ~~internal~~intellectual ~~control~~property ~~over~~rights ~~financial~~of ~~reporting~~third isparties, aand ~~process~~without ~~designed~~breaching toany ~~provide~~licenses ~~reasonable~~or ~~assurance regarding~~other ~~the~~agreements ~~reliability~~that ofwe ~~financial~~have ~~reporting~~entered ~~and~~into ~~the~~with ~~preparation~~regard ofto ~~financial~~our ~~statements~~technologies, ~~for~~products ~~external~~or ~~purposes~~services. inWe ~~accordance with~~cannot ~~accounting~~ensure ~~principles~~that ~~generally~~patents ~~accepted~~have innot ~~the~~been ~~United~~issued, ~~States~~or ofwill ~~America.~~not ~~Because~~be ~~of its inherent limitations~~issued, ~~internal~~to ~~control over~~third ~~financial~~parties ~~reporting~~that ~~may~~could ~~not~~block ~~prevent~~our orability ~~detect~~to ~~misstatements.~~obtain ~~Also,~~patents ~~projections~~or ofto ~~any~~operate ~~evaluation~~as ofwe ~~effectiveness~~would tolike. ~~future periods~~There ~~are~~may ~~subject~~be topatents ~~the~~in ~~risk~~some countries that, ~~controls~~if valid, may ~~become~~block ~~inadequate~~our ~~because~~ability ofto ~~changes~~make, inuse, ~~conditions~~sell, or ~~that~~offer ~~the~~for ~~degree~~sale ofour ~~compliance with~~technology, ~~the~~products, ~~policies~~ or ~~procedures~~services ~~may~~in ~~deteriorate.~~those ~~Under~~countries, ~~the~~or ~~supervision~~import ~~and~~our ~~with~~products ~~the~~into ~~participation~~those ~~of management~~countries, ~~including~~if ~~the Chief~~we ~~Executive~~are ~~Officer~~unsuccessful ~~and~~in ~~Chief~~circumventing ~~Financial~~or ~~Officer,~~acquiring ~~the~~rights ~~Company~~to ~~conducted~~these anpatents. ~~evaluation~~There ofalso ~~the~~may ~~effectiveness~~be ofclaims ~~the~~in ~~Company’s internal~~patent ~~control~~applications ~~over~~filed ~~financial~~in ~~reporting~~some ascountries ofthat, ~~July~~if 31granted and valid, ~~2018~~may ~~using~~also ~~the~~block ~~criteria~~our ~~established~~ability into ~~“Internal~~commercialize ~~Control~~technology, -products, ~~Integrated Framework”~~services, ~~issued~~or byprocesses ~~the~~in ~~Committee~~these ofcountries ~~Sponsoring~~if ~~Organizations~~we ofare ~~the~~unable ~~Treadway~~to ~~Commission~~circumvent ~~(“COSO”)~~or obtain rights to them.

~~A material~~Our ~~weakness~~investors ismay alose ~~deficiency,~~their orentire ~~combination~~investment ofbecause ~~deficiencies,~~our ~~in internal control over~~ financial ~~reporting,~~status ~~such~~creates ~~that there is~~ a ~~reasonable~~doubt ~~possibility~~whether ~~that~~we ~~a material misstatement of the Company’s annual or interim financial statements~~ will ~~not be~~continue ~~prevented~~as ~~or detected on~~ a ~~timely~~going ~~basis~~concern. In its assessment of the effectiveness of internal control over financial reporting as of July 31, 2018, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

We do not have ansufficient ~~Audit~~cash ~~Committee~~nor –do ~~While~~we ~~not~~have ~~being~~a ~~legally~~significant ~~obligated~~source of revenues to ~~have~~cover anour ~~audit~~operational ~~committee,~~costs itand isallow ~~the~~us ~~management’s view~~to ~~that~~continue ~~such~~as a ~~committee,~~going ~~including~~concern. The aCompany ~~financial~~anticipates ~~expert~~generating ~~member~~revenues from our future technology, isproducts, anand ~~utmost~~services ~~important~~and ~~entity~~if ~~level~~that ~~control~~is ~~over~~not ~~the~~sufficient ~~Company’s financial~~we ~~statement.~~may ~~Currently~~seek ~~the~~to ~~Board~~raise ofadditional ~~Directors~~operating ~~acts~~capital to implement our business plan in ~~the~~an ~~capacity~~offering of our common stock or debt. Our plan requires capital to operate for the ~~Audit~~next ~~Committee~~twelve months. However, ~~and~~there ~~does~~can ~~not~~be ~~include~~no aassurance ~~member~~ that isthe ~~considered~~revenues togenerated beor ~~independent~~that ofsuch ~~management~~an tooffering ~~provide~~will ~~the~~be ~~necessary~~successful. ~~oversight~~You ~~over~~may ~~management’s~~lose ~~activities.~~your entire investment

14We may not be able to enforce our intellectual property rights throughout the world.

~~We did~~The ~~not~~laws ~~implement~~of ~~appropriate~~some ~~information~~foreign ~~technology~~countries ~~controls~~where –we Asdo ofbusiness ~~July~~do ~~31,~~not ~~2018,~~protect intellectual property rights to the ~~Company~~same ~~retains~~extent ~~copies~~as the laws of ~~all~~the ~~financial data~~United States. Many companies have encountered significant problems in protecting and ~~material~~enforcing ~~agreements;~~intellectual ~~however~~property ~~there~~rights isin nocertain ~~formal~~foreign ~~procedure~~jurisdictions. orThe ~~evidence~~legal systems of ~~normal~~certain ~~backup~~countries, ofparticularly ~~the~~certain ~~Company’s~~developing ~~data~~countries, ~~or off-site~~do ~~storage~~not favor the enforcement of ~~data~~patents and other intellectual property rights. Accordingly, our efforts to protect and enforce our intellectual property rights in such countries may be inadequate. This could make it difficult for us to stop the ~~event~~infringement, violation or misappropriation of ~~theft,~~our ~~misplacement~~patents, or ~~loss~~other ~~due~~intellectual property rights. Additionally, proceedings to ~~unmitigated~~enforce ~~factors~~our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.

~~Accordingly, the~~Confidentiality ~~Company~~and ~~concluded~~non-use ~~that~~agreements ~~these~~with ~~control~~employees, ~~deficiencies~~consultants, ~~resulted~~advisors inand aother ~~reasonable~~third ~~possibility~~parties ~~that~~may ~~a material misstatement of the annual or interim financial statements will~~ not beadequately ~~prevented~~prevent ordisclosures ~~detected~~and onnon-use aof ~~timely~~trade ~~basis~~secrets byand ~~the~~other ~~company’s~~proprietary ~~internal controls~~information.

~~As a~~In ~~result~~addition ofto ~~the~~patent ~~material~~protection, ~~weaknesses~~we ~~described~~also ~~above~~rely on other intellectual property rights, ~~management~~including ~~has~~protection ~~concluded~~of copyright, trade secrets, know-how and/or other proprietary information that ~~the~~is ~~Company~~not ~~did~~patentable or that we elect not ~~maintain~~to ~~effective~~patent. ~~internal control~~However, ~~over~~trade ~~financial~~secrets ~~reporting~~can asbe difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of ~~July~~our 31trade secrets and proprietary information, ~~2018~~we ~~based~~rely in part on ~~criteria~~trade ~~established~~secret law and contractual agreements to protect our confidential and proprietary information and processes. We will generally enter into confidentiality and invention assignment agreements with our employees, consultants, and third parties working on our behalf upon their commencement of a relationship with us. However, trade secrets and confidential information are difficult to protect, and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes, and we may not enter into such agreements with all employees, consultants and third parties who have been involved in ~~Internal~~the ~~Control-~~development ~~Integrated~~of ~~Framework~~our ~~issued~~ intellectual property rights. Nevertheless, without our permission or awareness, our confidential and proprietary information may be disclosed to third parties, used by ~~COSO~~the respective individuals for purposes other than for the Company’s business, or obtained through illegal means, such that third parties could reverse engineer our biocatalysts, product candidates, and processes, to attempt to develop the same technology or develop substantially equivalent technology. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our confidential and proprietary rights, and failure to protect our trade secrets could adversely affect our competitive business position. If any of our trade secrets were lawfully obtained, we may be unable to prevent them, or those to whom they communicate it, from using that technology or information to compete with us or disclosing it publicly. Therefore, these events could have a material adverse effect of our business, financial condition, and results of operations. Any failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share.

~~Changes in~~18 ~~Internal~~Table ~~Control~~of ~~over Financial Reporting~~Contents

~~Pursuant to~~We aexpect ~~Change~~our ofquarterly ~~Control on May 10, 2018, the Company’s internal controls over its~~ financial ~~reporting~~results ~~were transferred~~ to ~~new~~ ~~management~~fluctuate. However, such control rested with the principal officer prior to the change of control and with the change of control it continues to rest with the new principal officer, the Company’s sole officer. Thus such change has not materially affected, or is not reasonably likely to materially affect, the Company’s internal control over financial reporting.

~~Attestation Report~~We expect our revenue and operating results to vary significantly from quarter to quarter due to a number of ~~Registered~~factors, ~~Public~~including ~~Accounting~~changes ~~Firm~~in:

~~This annual~~· ~~report~~General oneconomic ~~Form~~conditions; ~~10-K~~· ~~does~~The ~~not~~number ~~include~~of anclients ~~attestation~~for ~~report of~~ our ~~independent~~business ~~registered~~consulting ~~public~~services; ~~accounting~~· ~~firm,~~Our ~~regarding internal~~ability ~~controls~~to ~~over~~retain, ~~financial~~grow ~~reporting.~~our ~~Our~~business ~~internal~~and ~~control~~attract ~~over~~new ~~financial~~clients; ~~reporting~~· ~~was~~Administrative ~~not~~costs; ~~subject~~and, to· ~~such~~Advertising ~~attestation as~~and weother ~~are~~marketing ~~a smaller reporting company~~costs.

~~Changes~~ As a result of the variability of these and other factors, our operating results in ~~internal~~future ~~controls~~quarters may be below the expectations of public market analysts and investors.

~~As reported on the Form 8~~Dual-KClass ~~filed~~Capital byStructure ~~the~~Limits ~~Company with~~ the ~~SEC~~Ability ~~on May 15, 2018, as a result~~ of aOther ~~private~~Shareholders ~~transaction, 4,000,000 shares of common stock (the “Shares”) of Reliant were transferred from Stanislav Augustin~~ to ~~Zhu~~Influence ~~Ming,~~Corporate Wang Ye, Ma Chao, Piao Guigen, Zu Tianliang, Zhang Yulong, Yao Hongtao, Zhu Yukun, Chen Wei, Wu Chao, Wang Qinyu, Gao Hang, Ge Shiyang, Li Shuang, Wang Mingyu, Cao Delong, Jin Tong, Wang Zhiqian, Yang Wanli, Zhang Ye, Zhu Haoyu (the “Purchasers”). In connection with the transaction, Stanislav Augustin released the Company from all debts owed to him.Decisions

~~As reported~~We onhave ~~the~~a ~~Form 8~~dual-Kclass ~~filed~~capital bystructure ~~the~~consisting ~~Company~~of ~~with~~Series ~~the~~A ~~SEC~~and onSeries ~~May~~B ~~15,~~Preferred ~~2018~~Stock, ~~upon~~our ~~the~~Series ~~change~~A ofPreferred ~~control~~Stock ofcarries ~~the~~100 ~~Company~~votes ~~and~~per ~~the filing~~share of ~~the~~Series ~~quarterly~~A ~~report~~Preferred ~~for~~Stock ~~the~~and ~~period~~our ~~ending~~Series ~~April~~B ~~30,~~Preferred ~~2018,~~Stock ~~which~~carries ~~occurred~~500 onvotes ~~May~~per ~~10,~~share ~~2018,~~of ~~Stanislav~~Series ~~Augustin,~~B ~~the~~Preferred ~~then sole director and officer, resigned~~Stock. Accordingly, ~~Stanislav~~holders ~~Augustin,~~of ~~serving~~the asSeries ~~the~~A ~~sole~~Preferred ~~director~~Stock and asSeries ~~the~~B ~~only~~Preferred ~~officer~~Stock will, ~~ceased to~~for be the ~~Company’s~~foreseeable ~~President~~future, ~~Chief~~have ~~Executive~~voting ~~Officer,~~control ~~Treasurer,~~over ~~Secretary~~such ~~and~~matters ~~Director.~~requiring Atapproval ~~the~~by ~~effective~~shareholders, ~~date~~including, ofbut ~~the change~~not oflimited ~~control~~to, ~~following~~ the ~~filing~~election of ~~the~~directors ~~aforementioned~~and ~~Form~~the ~~10-Q,~~approval ~~Mr.~~of ~~Zhu~~mergers ~~Ming~~or ~~consented~~other tobusiness ~~act~~combination ~~as the new President~~transactions, ~~CEO, CFO,~~even ~~Treasurer,~~if ~~Secretary~~they ~~and~~hold ~~Chairman~~a minority of the ~~Board~~total ofoutstanding ~~Directors of the Company~~shares.

~~Other than~~Concentrated ~~the~~Voting ~~foregoing,~~Power ~~there~~May ~~was~~Result ~~no change~~ in ~~our~~Decisions ~~internal~~That ~~controls~~Do ~~over~~Not ~~financial~~Align ~~reporting~~with ~~that~~Minority ~~occurred~~Shareholders’ ~~during the period covered by this report, which has materially affected or is reasonably likely to materially affect, our internal controls over financial reporting.~~Interests

~~ITEM 9B~~Holders of our preferred stock have the ability to unilaterally approve corporate actions without requiring the consent of other shareholders. ~~OTHER~~This ~~INFORMATION~~could lead to corporate policies, strategic decisions, or transactions that disproportionately benefit controlling shareholders, even if they are not in the best interests of our common shareholders. Additionally, our dual-class capital structure may discourage potential merger, acquisition, or takeover attempts that could be beneficial to our shareholders. Because our preferred stock shareholders hold superior voting rights, they have the power to block transactions that may otherwise provide a premium to our common stockholders. This could result in missed opportunities for shareholder value maximization.

~~None.~~Risk of Unexpected Conversion or Dilution of Voting Power

15In the event of a issuances, conversions, or transfer of shares of our Series A and Series B Preferred Shares, our voting structure may change, impacting governance and control. Additionally, if we issue new shares of Series A or Series B Preferred Shares in the future, it could further dilute the voting power of our common stockholders.

~~PART III~~Our Shares are “Penny Stock,” which impairs trading liquidity.

~~ITEM 10~~Disclosure requirements pertaining to penny stocks may reduce the level of trading activity in the market for our Shares and investors may find it difficult to sell their Shares. ~~DIRECTORS~~The SEC has rules that regulate broker/dealer practices in connection with transactions in “penny stocks”. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, ~~EXECUTIVE~~provided ~~OFFICERS~~that ~~AND~~current ~~CORPORATE~~price ~~GOVERNANCE~~and volume information with respect to transactions in that security is provided by the exchange or system). The penny stock rules require a broker/dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the SEC that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker/dealer also must provide the operator with current bid and offer quotations for the penny stock, the compensation of the broker/dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the operator’s account. The bid and offer quotations, and the broker/dealer and salesperson compensation information, must be given to the operator orally or in writing prior to effecting the transaction and must be given to the operator in writing before or with the operator’s confirmation.

~~The name,~~19 ~~age~~Table ~~and titles~~ of ~~our executive officer and director is as follows:~~Contents

NAME	AGE		POSITION(S)	POSITION SINCE
Stanislav Augustin (1)		36	President, Chief Executive Officer, Secretary, Treasurer and Director	Appointed 03/20/2015 Resigned 05/10/2018
Zhu Ming (2)		37	President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Chairman of the Board of Directors	Appointed 05/10/2018

As an “Emerging Growth Company” any decision to comply with the reduced disclosure requirements applicable to emerging growth companies could make our Shares less attractive to investors.

(1)	Mr. Augustin resigned from his positions as President, Chief Executive Officer, Secretary, Treasurer and Director on May 10, 2018 as a result of the private transaction entered into on May 10, 2018.
(2)	Mr. Zhu Ming took office on May 10, 2018.

We are an “emerging growth company,” as defined in the JOBS Act, and, for as long as we continue to be an “emerging growth company,” we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues exceed $1 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our Shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

~~Mr. Zhu~~In ~~Ming~~addition, ~~age~~Section ~~37,~~107 ~~has~~of ~~been~~the ~~working~~JOBS asAct aalso ~~chief~~provides ~~editor~~that atan ~~Shanghai~~“emerging ~~Dongwen~~growth ~~Culture~~company” ~~Media~~can ~~Co.,~~take ~~Ltd.~~advantage ~~since~~of ~~February 2010. He was responsible for~~ the ~~magazine~~extended ~~interview~~transition ~~planning~~period ~~and management with company leaders. Between March 2015 and April 2017, Mr. Zhu~~ provided ~~service to~~in ~~Shanghai~~Section ~~Yiqu Co., Ltd as~~ 7(a)(2)(B) ~~vice president. He was responsible for the management and strategic planning~~ of the ~~company,~~Securities ~~in order~~Act tofor ~~develop~~complying ~~the~~with ~~business~~new ~~further~~or ~~with~~revised ~~his~~accounting ~~network~~standards. ~~Since~~In ~~April~~other ~~2017~~words, ~~Mr.~~an ~~Zhu~~“emerging ~~has~~growth ~~acted~~company” ascan adelay ~~general~~the ~~manager~~adoption inof ~~Shanghai~~certain ~~Transcy Technology~~accounting ~~Co.,~~standards ~~Ltd.,~~until ~~who~~those ~~was~~standards ~~responsible~~would ~~for~~otherwise ~~the~~apply ~~overall~~to ~~operation~~private ofcompanies. ~~the~~We ~~company,~~have ~~the~~elected ~~management~~to ~~policy~~opt ~~and~~into the ~~strategic~~extended ~~deployment. Mr.~~transition ~~Zhu~~period ~~obtained~~for ~~his~~complying ~~bachelor~~with ~~degree~~the inrevised ~~International~~accounting ~~Trades from Shenyang University in China~~standards.

~~Mr. Augustin,~~We ~~age~~May ~~36,~~Continue ~~has served as our President, Chief Executive Officer, Secretary, Treasurer and a Director from our inception on March 20, 2015~~ to ~~the~~Take ~~Change~~Advantage of ~~Control~~Reduced onReporting ~~May~~Requirements ~~10,~~Even ~~2018.~~If ~~Mr.~~We ~~Augustin~~No ~~has~~Longer ~~been~~Qualify ~~serving~~ as aan ~~marketing~~Emerging ~~director~~Growth ~~at a Czech Republic private home furniture company “Bytový nábytek s.r.o.” for the past ten years.~~Company

16Once we no longer qualify as an EGC, we may still be classified as a Smaller Reporting Company (“SRC”) under SEC rules if our public float is less than $250 million or, in certain cases, if our annual revenue is less than $100 million. As an SRC, we would continue to be eligible for scaled disclosure requirements, including reduced financial reporting obligations and less extensive executive compensation disclosures. While these accommodations allow us to reduce compliance costs, they may also limit the amount of publicly available information about our business, which could impact investor confidence or reduce analyst coverage of our stock. Additionally, there is no guarantee that we will remain an SRC indefinitely, and if we no longer qualify for this status, we will be required to comply with more extensive disclosure and compliance obligations, which could increase our legal, accounting, and administrative expenses.

~~Director Independence~~Our status as an “Emerging Growth Company” under the JOBS Act of 2012 may make it more difficult to raise capital.

~~We are~~Because ~~not~~of ~~currently~~the ~~subject~~exemptions tofrom ~~listing~~various reporting requirements ofprovided ~~any~~to ~~national~~us ~~securities~~as ~~exchange~~an or“emerging ~~inter-dealer~~growth ~~quotation~~company” ~~system~~and ~~which~~because ~~has requirements~~we ~~that~~will ahave ~~majority~~an ofextended ~~the~~transition ~~board~~period offor ~~directors~~complying with new or revised financial accounting standards, we may be ~~“independent”~~less ~~and~~attractive to investors, and it may be difficult for us to raise additional capital as aand ~~result,~~when we ~~are~~need ~~not~~it. atInvestors ~~this~~may ~~time required~~be unable to ~~have~~compare our ~~Board~~business ofwith ~~Directors~~other ~~comprised~~companies ofin aour ~~majority~~industry ofif ~~“independent~~they ~~directors.”~~believe ~~Our~~that ~~sole~~our ~~director~~financial accounting is not an ~~independent~~as ~~director~~transparent ~~under~~as ~~the~~other ~~applicable~~companies ~~standards~~in our industry. If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially and adversely affected.

~~Family Relationships~~20 Table of Contents

~~There are~~SPECIAL noNOTE ~~family~~REGARDING ~~relationships~~FORWARD-LOOKING ~~among our directors or executive officers.~~STATEMENTS

~~Involvement~~ Certain information contained in ~~Certain~~this ~~Legal~~Registration ~~Proceedings~~Statement includes forward-looking statements. The statements herein which are not historical reflect our current expectations and projections about the Company’s future results, performance, liquidity, financial condition, prospects, and opportunities and are based upon information currently available to the Company and its management and management’s interpretation of what is believed to be significant factors affecting the business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

~~Our sole~~· ~~director~~potential ~~and~~governmental ~~executive~~regulations ~~officer~~relating ~~has~~to ~~not~~or ~~been~~that ~~involved~~may impact our industry segments; · increased costs or exposure to liability as a result of changes in laws or regulations applicable to the biotransformation industry; · general volatility of the capital and credit markets and the market price of our Shares; · exposure to litigation or other claims; · loss of key personnel; · the risk that we may experience future net losses; · risks associated with breaches of our security; · failure to obtain necessary outside financing on favorable terms, or at all; · risks associated with future sales of our Shares by existing shareholders or the perception that they intend to sell substantially all of the Shares of our Company that they hold; · risks associated with the market for our Shares; or · any of the ~~following~~other ~~events~~risks ~~during~~included herein, including those set forth under the ~~past~~headings ~~ten~~“Risk ~~years:~~Factors,” “Board of Directors’ Discussion and Analysis of Financial Condition and Results of Operations” and “Our Business.”

●Forward-looking ~~any~~statements, ~~bankruptcy~~which ~~petition~~involve ~~filed~~assumptions byand ordescribe ~~against~~our ~~any~~future ~~business~~plans, ofstrategies, ~~which~~and ~~such~~expectations, ~~person~~are ~~was~~generally aidentifiable ~~general~~by ~~partner~~use orof ~~executive~~the ~~officer~~words ~~either~~“will,” at“shall,” ~~the~~“may,” ~~time~~“should,” of“expect,” ~~the~~“anticipate,” ~~bankruptcy~~“estimate,” or“believe,” ~~within~~“intend,” ~~two~~“plan,” ~~years~~or ~~prior~~“project” toor ~~that~~the ~~time;~~negative ●of ~~any~~these ~~conviction~~words inor aother ~~criminal~~variations ~~proceeding~~on orthese ~~being~~words ~~subject~~or tocomparable aterminology. ~~pending~~Actual ~~criminal~~results, ~~proceeding~~performance, ~~(excluding~~liquidity, ~~traffic~~financial ~~violations~~condition, prospects, and ~~other~~opportunities ~~minor~~could ~~offenses);~~differ ●materially ~~being~~from ~~subject~~those toexpressed ~~any order~~in, ~~judgment,~~ or ~~decree,~~implied ~~not subsequently reversed~~by, ~~suspended~~these orforward-looking ~~vacated,~~statements ofas ~~any~~a ~~court~~result of ~~competent~~various ~~jurisdiction~~risks, ~~permanently~~uncertainties, orand ~~temporarily~~other ~~enjoining~~factors, ~~barring,~~including ~~suspending~~the orability ~~otherwise~~to ~~limiting~~raise ~~his~~sufficient orcapital ~~her~~to ~~involvement~~continue inthe ~~any~~Company’s ~~type~~operations. ofActual ~~business,~~events ~~securities~~ or ~~banking~~results ~~activities;~~may ordiffer ●materially ~~being~~from ~~found~~those bydiscussed in forward-looking statements as a ~~court~~result of ~~competent~~various ~~jurisdiction~~factors, ~~(in~~including, awithout ~~civil action)~~limitation, the ~~Commission~~risks oroutlined ~~the~~under ~~Commodity~~“Risk ~~Futures~~Factors” ~~Trading~~and ~~Commission~~matters todescribed ~~have~~in ~~violated~~this aRegistration ~~federal~~Statement orgenerally. ~~state~~In ~~securities~~light orof ~~commodities~~these ~~law,~~risks and uncertainties, there can be no assurance that the ~~judgment~~forward- ~~has~~looking ~~not~~statements ~~been~~contained ~~reversed,~~in ~~suspended,~~this orRegistration ~~vacated~~Statement will in fact occur.

~~Board Committees~~Accordingly, prospective investors should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward- looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

The ~~Company~~ ~~currently~~specific ~~has~~discussions ~~not~~herein ~~established~~about ~~any committees of~~ the ~~Board~~Company ofinclude ~~Directors.~~financial ~~Our~~projections ~~Board~~and offuture ~~Directors~~estimates ~~may~~and ~~designate~~expectations ~~from~~about ~~among its~~the ~~members~~Company’s anbusiness. ~~executive~~The ~~committee~~projections, estimates and ~~one~~expectations orare ~~more~~presented ~~other committees~~ in ~~the~~this ~~future.~~Registration WeStatement doonly ~~not~~as ~~have~~ a ~~nominating~~guide ~~committee~~about orfuture ~~a nominating~~possibilities ~~committee~~and ~~charter. Further, we~~ do not ~~have~~represent aactual ~~policy~~amounts ~~with~~or ~~regard~~assured ~~to the consideration of any director candidates recommended by security holders~~events. ToAll ~~date,~~the ~~other~~projections ~~than~~and asestimates ~~described~~are ~~above,~~based noexclusively ~~security~~on ~~holders~~the ~~have~~officers ~~made~~of ~~any~~the ~~such~~Company’s ~~recommendations.~~own ~~The~~assessment ~~entire Board~~ of ~~Directors~~its ~~performs~~business, ~~all functions that would otherwise be performed by committees. Given~~ the ~~present~~industry ~~size~~in ofwhich ~~our board,~~ it isworks ~~not~~and ~~practical~~the ~~for~~economy usat tolarge ~~have~~and ~~committees.~~other Ifoperational wefactors, ~~are~~including ~~able~~capital toresources ~~grow~~and ~~our~~liquidity, ~~business~~financial ~~and~~condition, ~~increase~~fulfillment ~~our~~of ~~operations~~contracts, weand ~~intend~~opportunities. toThe ~~expand the~~actual ~~size~~results ofmay ~~our~~differ ~~board~~significantly ~~and~~from ~~allocate~~the ~~responsibilities accordingly~~projections.

17Litigation

~~Audit Committee~~In ~~Financial~~the ~~Expert~~ordinary course of its business, the Company may be subject to litigation from time to time. The outcome of such proceedings may materially adversely affect the value of the Company and may continue without resolution for long periods of time. Any litigation may consume substantial amounts of the Board of Directors' time and attention, and such time and resources devoted to such litigation may, at times, be disproportionate to the amounts at stake in such litigation.

~~We have~~21 noTable ~~separate audit committee at this time. The entire Board~~ of ~~Directors oversees our audits and auditing procedures. Our director is not an “audit committee financial expert” within the meaning of Item 407(d)(5) of SEC Regulation S-K.~~Contents

~~Compensation Committee~~INDUSTRY AND OTHER DATA

This prospectus contains industry, market and competitive position data from our own internal estimates and research as well as industry and general publications and research surveys and studies conducted by third parties. We ~~have~~ nodid ~~separate~~not ~~compensation~~commission ~~committee~~any atof the third-party data identified throughout this ~~time~~prospectus. ~~The~~Industry ~~entire~~publications, ~~Board~~studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of ~~Directors~~such ~~oversees~~information. Our internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the ~~functions~~markets in which ~~would~~we beoperate ~~performed~~ and our management’s understanding of industry conditions. While we believe that each of these studies and publications is reliable, we have not independently verified market and industry data from third-party sources. While we believe our internal company research is reliable and the market definitions are appropriate, neither such research nor definitions have been verified by aan ~~compensation~~independent ~~committee~~source.

~~Code~~ The industry in which we operate is subject to risks and uncertainties due to a variety of ~~Ethics~~factors, including those described in the section titled “Risk Factors.” These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

~~Due to~~ITEM our size, a limited number of employees, the fact that we presently only have one director and one officer and are still in the development stage of our operations, the Company has not yet adopted a Code of Ethics which applies to our directors, officers, employees and representatives1B. WeUNRESOLVED ~~intend~~STAFF ~~to adopt a code of ethics when we increase either the number of our directors and officers or the number of our employees~~COMMENTS.

~~ITEM 11.~~This ~~EXECUTIVE~~item ~~COMPENSATION~~is not applicable to the Company because the Company is a smaller reporting company as defined by Rule 12b-2 under the Securities Exchange Act of 1934.

~~No current~~ITEM or prior officer or director has received any remuneration or compensation from the Company in the past year, nor has any member of the Company’s management been granted any option or stock appreciation right1C. Accordingly, no tables relating to such items have been included within this Item. None of our officers have received a cash salary since our founding. The Company has no agreement or understanding, express or implied, with any director, officer or principal stockholder, or their affiliates or associates, regarding compensation in the form of salary, bonuses, stocks, options, warrants or any other form of remuneration, for services performed on behalf of the Company. Nor are there compensatory plans or arrangements, including payments to any officer in relation to resignation, retirement, or other termination of employment, or any change in control of the Company, or a change in the officer’s responsibilities following a change in control of the Company.CYBERSECURITY

18Risk Management and Strategy

~~ITEM 12~~Our cybersecurity policies, standards, processes, and practices are based on applicable laws and regulations and informed by industry standards and industry-recognized practices. ~~SECURITY~~Our ~~OWNERSHIP~~strategy OFto ~~CERTAIN~~assess, ~~BENEFICIAL~~identify, ~~OWNERS~~and ~~AND~~manage ~~MANAGEMENT~~material ~~AND~~cybersecurity ~~RELATED~~risks ~~STOCKHOLDER~~is ~~MATTERS~~through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security, and availability of our information systems and data. We implement security measures and processes to identify, prevent, and mitigate cybersecurity threats and to effectively respond to cybersecurity incidents when they occur. Our cyber risk management includes: (1) enterprise risk management to identify top cybersecurity risks; (2) vulnerability management to identify software vulnerabilities and risks related to compute infrastructure; (3) vendor risk management to identify risks related to third parties and business partners, which includes pre-engagement review, use of contractual security provisions, and continued monitoring, as applicable; (4) privacy risk management to identify privacy risks in our product and platforms and ensure regulatory compliance; (5) security monitoring to analyze and assess threat activity in real time; and (6) security incident response to investigate, respond to, and mitigate cyber threats. We regularly engage third parties to identify risks in our underlying software and infrastructure, to provide threat intelligence, and to assist in triaging, identifying, and responding to cyber threats.

~~The following~~No ~~table~~material ~~lists,~~cybersecurity asincidents ofwere ~~the~~identified ~~date~~as of ~~this~~filing ~~annual~~date. ~~report~~We onhave ~~Form~~not ~~10-K,~~identified ~~the~~any ~~number~~cybersecurity ofthreats ~~shares of common stock of our Company~~ that ~~are~~have ~~beneficially~~materially ~~owned~~affected ~~by (i) each person~~ or ~~entity~~are ~~known~~reasonably tolikely ~~our Company~~ to bematerially ~~the~~affect ~~beneficial owner of more than 5% of the outstanding common stock; (ii) each officer and director of~~ our ~~Company;~~business ~~and~~strategy, ~~(iii)~~results ~~all officers and directors as a group. Information relating to beneficial ownership~~ of ~~common~~operations, ~~stock~~or byfinancial ~~our principal shareholders and management is based upon information furnished by each person using “beneficial ownership” concepts under the rules of the Securities and Exchange Commission~~condition. ~~Under these rules~~ However, adespite ~~person~~our ~~is deemed to be a beneficial owner of a security if that person has or shares voting power~~efforts, ~~which~~we ~~includes the~~cannot ~~power~~eliminate toall ~~vote~~risks orfrom ~~direct~~cybersecurity ~~the voting of the security~~threats, or ~~investment~~provide ~~power,~~assurances ~~which includes the power to vote or direct the voting of the security. The person is also deemed to be a beneficial owner of any security of which~~ that ~~person~~we ~~has~~have a right to acquire beneficial ownership within 60 days. Under the Securities and Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not ~~have~~experienced ~~any~~undetected ~~pecuniary~~cybersecurity ~~beneficial interest~~incidents. ~~Except as noted below, each person has sole voting and investment power.~~

The percentages below are calculated based on 5,015,000 shares of our common stock issued and outstanding as of the date of this report. We do not have any outstanding warrant, options or other securities exercisable for or convertible into shares of our common stock.Governance

	Name and Address	Number of Shares		Percent of Class
Title of Class	of Beneficial Owner(1)	Owned Beneficially		Owned
Common Stock:	Zhu Ming, President, Chief Executive Officer, Secretary, Treasurer and Director		2,600,000		51.8	%
All executive officers and directors as a group			2,600,000		51.8	%

Our Board of Directors maintains oversight of risks from cybersecurity threats by meeting with and receiving periodic updates from our Chief Executive Officer, who is assigned oversight of cybersecurity risks. Our Chief Executive Officer is responsible for ensuring that management has processes in place designed to identify and evaluate cybersecurity risks to which the Company is exposed and to implement processes and programs to manage cybersecurity risks and mitigate cybersecurity incidents.

~~A beneficial~~ITEM owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares2. ~~Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares)~~PROPERTIES. In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

~~ITEM 13~~Our office is located in a shared office space which presently is sufficient for our needs, and we pay approximately $500.00 ~~CERTAIN~~a ~~RELATIONSHIPS~~month, ~~RELATED~~which ~~TRANSACTIONS~~we ~~AND~~believe ~~DIRECTOR~~will ~~INDEPENDENCE~~suffice for our immediate needs. Management does not anticipate any issue in locating and securing additional office space as we implement our plan of operation and the business grows.

~~As of~~ITEM ~~July~~3. ~~31,~~LEGAL 2018, there were advances of $1,939 from the CEO, Zhu Ming for the purpose of operating the Company; however, such balances were waived and were accounted for as an addition to additional paid in capitalPROCEEDINGS.

19The Company may, from time to time, be involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. There are no material pending or threatened legal proceedings at this time.

ITEM 14 4. ~~PRINCIPAL~~MINE ~~ACCOUNTANT~~SAFETY ~~FEES AND SERVICES~~DISCLOSURES.

~~The following~~Not ~~table shows the fees that were billed for the audit and other services for 2018 and 2017~~applicable.

	2018		2017
Audit Fees	$	8,000	$	3,250
Audit-Related Fees		-		-
Tax Fees		-		-
All Other Fees		-		-
Total	$	8,000	$	3,250

Table of Contents

~~Audit Fees~~PART consist of the aggregate fees billed for professional services rendered for the audit of our annual financial statements and the reviews of the financial statements included in our Forms 10-Q and for any other services that were normally provided by our independent auditor, respectively, in connection with our statutory and regulatory filings or engagements.II

~~Tax Fees~~Market consist of the aggregate fees billed for professional services rendered for tax compliance, tax advice and tax planning. Included in such Tax Fees were fees for preparation of our tax returns and consultancy and advice on other tax planning matters.Information

~~All Other~~Our ~~Fees~~Common ~~consist~~Stock ofis quoted on the ~~aggregate~~OTC ~~fees~~Markets ~~billed~~Group, ~~for~~Inc.’s ~~products~~PINK ~~and~~tier ~~services~~under ~~provided~~the bysymbol ~~our~~“QTZM” ~~independent~~On ~~and~~July ~~not~~31, ~~otherwise~~2025, ~~included in~~the ~~Audit~~closing ~~Fees,~~bid ~~Audit~~price ~~Related~~of ~~Fees~~our orCommon ~~Tax~~Stock ~~Fees~~was $0.30 ~~Included~~per inshare. ~~such~~The ~~Other~~bid ~~Fees~~quotations ~~were~~reported ~~fees~~on ~~for~~the ~~services~~OTC ~~rendered~~Pink byMarket ~~our~~reflect ~~independent auditor~~inter-dealer inprices, ~~connection~~without ~~with~~retail ~~our~~markup, ~~private~~markdown or commissions, and ~~public~~may ~~offerings~~not ~~conducted~~necessarily ~~during~~represent ~~such~~actual ~~periods~~transactions.

20Holders

~~PART IV~~As of July 31, 2025, we had 38,962,050 shares of common stock, par value $0.00001 per share, issued and outstanding, which were held by approximately 134 shareholders of record. The transfer agent for our securities is Old Monmouth Stock Transfer, 200 Memorial Parkway, Atlantic Highlands, NJ 07716, Phone: 732-872-2727.

~~ITEM 15.~~Recent ~~EXHIBITS,~~Sales ~~FINANCIAL~~of ~~STATEMENT~~Unregistered ~~SCHEDULES~~Securities

~~(1) All~~None. ~~financial statements~~

~~The following~~ITEM ~~documents~~6. ~~are filed as part of this report:~~[RESERVED]

~~(a) Financial~~ITEM ~~Statements~~7. ~~and~~MANAGEMENT’S ~~Report~~DISCUSSION ofAND ~~Independent~~ANALYSIS ~~Registered~~OF ~~Public~~FINANCIAL ~~Accounting~~CONDITION ~~Firm,~~AND ~~which~~RESULTS ~~are~~OF ~~set forth in the index to Financial Statements on pages F-1 through F-10 of this report~~OPERATIONS.

~~(2) Financial~~The ~~Statement~~following ~~Schedules~~discussion should be read in conjunction with our audited financial statements and the related notes included in this Annual Report on Form 10-K. This section contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed under “Risk Factors” and elsewhere in this report.

~~All financial~~Results ~~statement~~of ~~schedules~~Operations ~~have~~for ~~been omitted, since~~ the ~~required~~years ~~information~~ended isJuly ~~not applicable or is not present in amounts sufficient to require submission of the schedule~~31, or2025 ~~because the information required is included in the consolidated financial statements~~ and ~~notes thereto included in this Annual Report on Form 10-K.~~2024

~~(3) Exhibits~~Revenues

Number		Description
3.1*		Articles of Incorporation (Incorporated by reference from the Company’s Registration Statement on Form S-1, as amended; filed with the SEC on January 11, 2016)
3.2*		Bylaws (Incorporated by reference from the Company’s Registration Statement on Form S-1, as amended; filed with the SEC on January 11, 2016)
31.1**		Certification of Chief Executive Officer and Principal Financial Officer, pursuant to SEC Rules 13a-14(a) and 15d-14(a), adopted pursuant Section 302 of the Sarbanes Oxley Act of 2002
32.1***		Certification by Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350

We earned no revenues for the years ended July 31, 2025 or 2024.

101.INS**		XBRL Instance Document **
101.SCH XBRL**		Taxonomy Extension Schema Document **
101.CAL XBRL**		Taxonomy Extension Calculation Linkbase Document **
101.DEF XBRL**		Taxonomy Extension Definition Linkbase Document **
101.LAB XBRL**		Taxonomy Extension Label Linkbase Document XBRL **
101.PRE XBRL**		Taxonomy Extension Presentation Linkbase Document **

Operating Expenses

*We ~~Previously~~incurred ~~filed~~$180,537 **in ~~Filed~~operating ~~herewith~~expenses ~~***~~for ~~Furnished~~the ~~herewith~~year ended July 31, 2025, as compared with $163,593 in the year ended July 31, 2024. The increase in operating expenses is the result increased in professional fees during the year ended July 31, 2025. We expect our operating expenses will increase in future years as a result of the costs associated with the increased operating activity under our business model.

~~ITEM 16.~~23 ~~FORM~~Table ~~10–K~~of ~~SUMMARY~~Contents

~~None.~~Other Income/Expenses

21We had other expenses of $18,732 for the year ended July 31, 2025, compared to other expenses of $14,976 for the year ended July 31, 2024. The increase in other expenses was the result of increased interest expense associated additional debt incurred during the year ended July 31, 2025.

~~SIGNATURES~~Net Loss

~~Pursuant to~~We ~~the~~recorded ~~requirements~~a net loss of ~~Section~~$199,269 13for orthe ~~15(d)~~year ofended ~~the~~July ~~Securities~~31, ~~Exchange~~2025, ~~Act~~compared ofto ~~1934~~a net loss $178,569 for the ~~registrant~~year ~~has~~ended ~~duly~~July ~~caused~~31, ~~this~~2024. ~~report to~~The bedecrease ~~signed~~in onnet ~~its~~loss ~~behalf~~was byassociated with the ~~undersigned,~~factors ~~thereunto~~discussed ~~duly authorized~~above.

Date: November 20, 2018	RELIANT SERVICE INC.
	By:	/s/ Zhu Ming
	Name:	Zhu Ming
	Title:	Chief Executive Officer

Going Concern

22The accompanying financial statements have been prepared in US dollars and in accordance with accounting principles generally accepted in the United States (“GAAP”) on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During the year ended July 31, 2025, the Company incurred net losses of $199,269, accumulated deficits of $5,636,567, and used cash in operations in the amount of $125,180. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

~~RELIANT SERVICE~~We ~~INC~~are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner. We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all. The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations. Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock. If we are unable to obtain necessary financing, we will likely be required to curtail our development plans. Any additional equity financing may involve substantial dilution to our then existing stockholders.

Contents:		Page
Report of Independent Registered Public Accounting Firm		F-1
Audited Balance Sheets		F-2
Audited Statements of Operations and Comprehensive Loss		F-3
Audited Statements of Stockholders’ Deficiency		F-4
Audited Statements of Cash Flows		F-5
Notes to Audited Financial Statements		F-6 - F-10

Table of Contents

23Liquidity and Capital Resources

~~REPORT OF~~Our ~~INDEPENDENT~~financing ~~REGISTERED~~objective ~~PUBLIC~~is ~~ACCOUNTING~~to ~~FIRM~~maintain financial flexibility to meet the material, equipment and personnel needs to support our project commitments and pursue our expansion and diversification objectives.

~~To the~~As ~~Board~~of July 31, 2025, we had total current assets of ~~Directors~~$584 and total current liabilities of $441,302. We had a working capital deficit of $440,718 as of July 31, 2025.

~~Stockholders of~~Net ~~Reliant~~cash ~~Service~~used ~~Inc~~by operating activities was $125,181 for the year ended July 31, 2025, as compared with $101,637 cash used for the year ended July 31, 2024. Our negative operating cash flow for both periods was our net losses, as adjusted to reconcile net loss to net cash provided by operating activities.

~~Opinion on~~Financing activities provided $125,765 in cash for the ~~Financial~~year ~~Statements~~ended July 31, 2025, as compared with $101,637, for the year ended July 31, 2024. The increase in cash provided by financing activities was the result of proceeds provided through the issuance of common stock during the year ended July 31, 2025.

~~We have~~Critical ~~audited~~Accounting the accompanying balance sheets of Reliant Service Inc. (the Company) as of July 31, 2018, and the related statements of operations, stockholders’ equity, and cash flows for the year ended July 31, 2018, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of July 31, 2018, and the results of its operations and its cash flows for the year ended July 31, 2018, in conformity with accounting principles generally accepted in the United States of America.Policies

~~The accompanying~~Our financial statements ~~have~~are ~~been~~ prepared ~~assuming~~in ~~that~~accordance ~~the~~with ~~Company~~U.S. ~~will~~generally ~~continue~~accepted asaccounting aprinciples ~~going concern~~(“GAAP”). AsThe ~~discussed in~~preparation ~~Note~~of 3these ~~to the~~ financial statements, ~~the~~requires ~~Company~~us ~~had~~to ~~incurred~~make ~~substantial~~estimates ~~losses~~and inassumptions ~~previous~~that ~~years~~affect ~~and~~the ~~has~~reported aamounts ~~working~~of ~~capital deficit~~assets, ~~which~~liabilities, ~~raises~~revenues, ~~substantial~~and ~~doubt~~expenses. ~~about~~Because ~~its~~we ~~ability~~are ~~to continue as~~ a ~~going~~development-stage ~~concern.~~company ~~Management’s~~with ~~plans~~limited inoperations, ~~regards to~~our ~~these~~critical ~~matters~~accounting ~~are~~policies ~~also~~primarily ~~described~~relate into ~~Note~~the 3.valuation ~~These~~of ~~financial~~equity ~~statements~~issuances, dostock-based ~~not~~compensation, ~~include~~and ~~any~~the ~~adjustments~~assessment ~~that~~of ~~might~~our ~~result~~ability ~~from the~~to ~~outcome~~continue ofas ~~this~~a ~~uncertainty~~going concern.

~~Basis for~~ITEM ~~Opinion~~7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

~~These financial~~This ~~statements~~item ~~are~~is ~~the~~not ~~responsibility~~applicable ofto the Company’s ~~management.~~because ~~Our responsibility is to express an opinion on~~ the Company’s ~~financial~~is ~~statements based on our audits. We are~~ a ~~public~~smaller ~~accounting~~reporting ~~firm~~company ~~registered~~as ~~with~~defined ~~the~~by ~~Public~~Rule ~~Company Accounting~~12b-2 ~~Oversight~~under ~~Board (United States) (PCAOB) and are required to be independent with respect to~~ the ~~Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the~~ Securities ~~and~~ Exchange ~~Commission~~Act ~~and~~of ~~the PCAOB~~1934.

~~We conducted~~ITEM ~~our audits in accordance with the standards of the PCAOB~~8. ~~Those~~FINANCIAL ~~standards~~STATEMENTS ~~require~~AND ~~that~~SUPPLEMENTARY ~~we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud~~DATA. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

~~Our audits~~All ~~included performing procedures to assess the risks of material misstatement of the~~ financial ~~statements,~~information ~~whether~~required ~~due~~by ~~to error~~this orItem ~~fraud,~~is ~~and performing procedures that respond to those risks. Such procedures~~ included ~~examining,~~ on ~~a test basis, evidence regarding~~ the ~~amounts~~pages ~~and~~immediately ~~disclosures~~following in the ~~financial~~Index ~~statements.~~to ~~Our~~Financial ~~audits~~Statements ~~also~~appearing ~~included~~on ~~evaluating~~page ~~the~~F-1 ~~accounting principles used~~ and ~~significant~~is ~~estimates~~hereby ~~made~~incorporated by ~~management, as well as evaluating the overall presentation of the financial statements~~reference. ~~We believe that our audits provide a reasonable basis for our opinion.~~

~~WWC,~~ITEM P9.C. ~~Certified~~CHANGES ~~Public~~IN ~~Accountants~~AND WeDISAGREEMENTS ~~have~~WITH ~~served~~ACCOUNTANTS asON ~~the~~ACCOUNTING ~~Company’s~~AND ~~auditor~~FINANCIAL ~~since 2018~~DISCLOSURE. ~~San Mateo, California November 20, 2018~~

~~F-1~~None

~~RELIANT SERVICE~~ITEM ~~INC~~9A. CONTROLS AND PROCEDURES.

~~AUDITED BALANCE~~Disclosure ~~SHEETS~~Controls and Procedures

~~AS OF~~Based ~~JULY~~on 31an evaluation as of the date of the end of the period covered by this report, ~~2018~~the ~~AND~~Company’s ~~2017~~Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures, as required by Rule 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that, because of the disclosed material weaknesses in the Company’s internal control over financial reporting, the Company’s disclosure controls and procedures were ineffective as of the end of the period covered by this report to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

	2018			2017
ASSETS
Current Assets
Cash and cash equivalents	$	-		$	2,744
Income tax benefit		-			4,704
Total Current Assets		-			7,448
Fixed Assets
Czech Office Building		-			11,900
Less Accumulated Depreciation		-			(1,305	)
Total Fixed Assets		-			10,595
Total Assets	$	-		$	18,043
Current Liabilities
Accounts Payable	$	524		$	-
Advances from Related Party		-			100
Accrued Liabilities		8,000			-
Total Current Liabilities		8,524			100
Stockholders’ (Deficiency)/Equity
Common stock, $0.001 par value, 75,000,000 shares authorized; 5,015,000 shares issued and outstanding as of July 31, 2018 and 2017	$	5,015		$	5,015
Additional Paid-In Capital		41,285			39,585
Accumulated Deficit		(54,824	)		(26,657	)
Total Stockholders’ (Deficiency)/Equity		(8,524	)		17,943
Total Liabilities & Stockholders’ (Deficiency)/Equity	$	-		$	18,043

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is accumulated and communicated to management, including the Company’s Chief Executive Officer and the Company’s Chief Financial Officer, to allow timely decisions regarding required disclosure.

~~The notes~~25 ~~are~~Table ~~an integral part~~ of ~~these audited financial statements~~Contents

~~F-2~~Management’s Annual Report on Internal Control Over Financial Reporting

~~RELIANT SERVICE~~Management ~~INC~~is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Exchange Act Rule 13a-15(f). Management conducted an evaluation of the effectiveness of the internal control over financial reporting as of July 31, 2025, using the criteria established in Internal Control – Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

~~AUDITED STATEMENT~~A OFmaterial ~~OPERATIONS~~weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. As a result of management’s assessment, management has determined that there are material weaknesses due to the lack of segregation of duties and, due to the limited resources based on the size of the Company. Due to the material weaknesses management concluded that as of July 31, 2025, the Company’s internal control over financial reporting was ineffective. In order to address and resolve the weaknesses, the Company will endeavor to locate and appoint additional qualified personnel to the board of directors and pertinent officer positions as the Company’s financial means allow. To date, the Company’s limited financial resources have not allowed the Company to hire the additional personnel necessary to address the material weaknesses.

~~FOR THE~~This ~~YEARS~~annual ~~ENDED~~report ~~JULY~~does ~~31,~~not ~~2018~~include ~~AND~~an ~~2017~~attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report.

	2018			2017
REVENUES
Merchandise Sales	$	93,550		$	128,147
COST OF SALES
Cost of Goods Sold		89,345			105,847
Gross Profit		4,205			22,300
Operating Expenses		17,121			60,957
Total Expenses		17,121			60,957
Other income/(expense):
Other Income		100			-
Other Expense		(15,351	)		-
Total other income/(expense):		(15,251	)		-
Loss Before Income Taxes		(28,167	)		(38,657	)
Income Tax Benefit (Provision)		-			5,799
Net Loss	$	(28,167	)	$	(32,858	)
Net Loss Per Basic and Diluted share		(0.00	)		(0.00	)
Weighted average number of Common Shares outstanding		5,015,000			5,015,000

Changes in Internal Control Over Financial Reporting

~~The notes~~There ~~are~~have anbeen ~~integral~~no ~~part~~changes in the Company’s internal control over financial reporting that occurred during the Company’s last fiscal quarter (the Company’s fourth fiscal quarter in the case of ~~these~~an ~~audited~~annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial ~~statements~~reporting.

~~F-3~~The term “internal control over financial reporting” is defined as a process designed by, or under the supervision of, the registrant’s principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

~~RELIANT SERVICE~~(a) ~~INC~~Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant; (b) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and (c) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant’s assets that could have a material effect on the financial statements.

~~AUDITED STATEMENT~~ITEM OF9B. ~~CHANGES~~OTHER ~~OF STOCKHOLDERS’ DEFICIENCY~~INFORMATION.

~~FOR THE~~During ~~YEARS~~the ~~ENDED~~year ~~JULY~~ended July 31, ~~2018~~2025, ~~AND~~none ~~2017~~of our directors or executive officers adopted or terminated a Rule 10b5-1 trading plan or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).

	Common Stock						Retained			Total
	Number of				Additional		Earnings/			Stockholders’
	Shares				Paid-in		(Accumulated			Equity/
	Outstanding		Par Value		Capital		Deficit)			(Deficiency)
Balance August 1, 2016		4,000,000	$	4,000	$	-	$	6,201		$	10,201
Issuance of shares for cash		1,015,000		1,015		39,585		-			40,600
Net loss		-		-		-		(32,858	)		(32,858	)
Balance July 31, 2017		5,015,000	$	5,015	$	39,585	$	(26,657	)	$	17,943
Balance August 1, 2017		5,015,000	$	5,015	$	39,585	$	(26,657	)	$	17,943
Current shareholder waiver of liabilities		-		-		1,700		-			1,700
Net loss		-		-		-		(28,167	)		(28,167	)
Balance July 31, 2018		5,015,000	$	5,015	$	41,285	$	(54,824	)	$	(8,524	)

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

~~The notes~~Not ~~are an integral part of these audited financial statements~~applicable.

~~F-4~~26 Table of Contents

~~RELIANT SERVICE~~PART ~~INC~~III

~~AUDITED STATEMENT~~ITEM OF10. ~~CASH~~DIRECTORS, ~~FLOWS~~EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE.

~~FOR THE~~The ~~YEARS~~Company’s ~~ENDED~~current ~~JULY~~directors ~~31,~~and ~~2018~~executive ~~AND~~officers ~~2017~~are as follows:

	2018			2017
Name	Age		Position(s)
CASH FLOWS FROM OPERATING ACTIVITIES
Naveen Krishnarao Kulkarni(1)	49		Chief Executive Officer, President, Secretary, Treasurer, Director
Net loss	$	(28,167	)	$	(32,858	)
Manu Bharath Khareedhi(2)	37		Independent Director
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Shrutin Ashok Ulman(2)	55		Independent Director
Impairment of assets		10,160			-
Gain on waiver of liabilities from former shareholder		1,600			-
Depreciation		435			580
Changes in operating assets and liabilities:
Decrease/(increase) in income tax benefit		4,704			(4,704	)
Decrease in income tax payable		-			(1,095	)
Increase in accounts payable and accrued liabilities		8,524			-
Net cash used in operating activities		(2,744	)		(38,077	)
CASH FLOWS FROM INVESTING ACTIVITIES
Assumption of cash from former shareholder		-			-
Net cash used in investing activities		-			-
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock		-			40,600
Net cash provided by financing activities		-			40,600
Net increase (decrease) in cash		(2,744	)		2,523
Cash at beginning of year		2,744			221
Cash at end of year	$	-		$	2,744
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during year for:
Interest Expense	$	-		$	-
Income Taxes	$	-		$	-
NONCASH FINANCING ACTIVITIES:
Waiver of liabilities from former director	$	100		$	-
Waiver of liabilities from current director	$	1,700		$	-

~~The notes~~Term ~~are an integral part~~ of ~~these audited financial statements~~Office

~~F-5~~All the Company’s directors hold office until the next annual meeting of the stockholders or until their successors is elected and qualified. The Company’s executive officers are appointed by the Company’s board of directors and hold office until their resignation, removal, death or retirement.

~~NOTE 1~~Background -and ~~ORGANIZATION~~Business ~~AND NATURE OF BUSINESS~~Experience

~~Reliant Service~~The ~~Inc.~~business ~~(the~~experience ~~“Company”)~~during ~~was~~the ~~incorporated~~past infive ~~the~~years ~~state~~ of ~~Nevada~~each onof ~~March 20, 2015. The company develops marketing channels to distribute office equipment to~~ the ~~wholesale~~Company’s ~~market~~directors inand ~~the~~executive ~~United~~officers ~~States. Our functional currency~~ is ~~the~~as ~~US Dollar and all the references to currency in the financial statements are in US Dollars.~~follows:

~~Basis of~~Management ~~Presentation~~Biographies:

~~The~~ Naveen Krishnarao Kulkarni – Mr. Kulkarni has two and a half decades of healthcare & biotech experience covering a broad range of scientific, entrepreneurial and innovation strategies in markets spanning Europe, the USA, Australia, and India. From 2017 through February 2023, when the Company ~~prepares~~acquired ~~its~~various ~~financial~~assets ~~statements~~from Mr. Kulkarni, Mr. Kulkarni was working on and formulating the ~~accrual~~concept ~~basis~~and business model of ~~accounting~~what would become the current iteration of the Company. To this end, he was instrumental in ~~accordance~~raising ~~with~~seed ~~accounting~~capital, ~~principles~~implementing ~~generally accepted~~the initial business plan and plan of operations, and positioning the company to operate as an IP driven business. From 2011 to 2016, Mr. Kulkarni was a Director and CEO of Cryo Stemcell Pvt. Ltd. where he was instrumental in the ~~United~~turnaround ~~States~~of the company from a stem cell banking service provider to a healthcare company. He also developed a business plan for next level funding and initiated PRP therapy and hospital partnerships with new customer acquisition and sales team mobilization plan for India. From November 2007 to October 2011, Mr. Kulkarni was a director at Philips Research, Asia, where he was involved in identifying and developing ventures for spin-ups, spin-ins and spin-outs in Philips with a portfolio of ~~America~~opportunities ~~(GAAP)~~for new business creation across healthcare and energy relevant for India, emerging markets and globally. We believe that Mr. Kulkarni possesses attributes that qualify him to serve as a member of the Board, including his leadership skills, and experience.

~~NOTE 2~~Dr. -Manu ~~SUMMARY~~Bharath OF– ~~SIGNIFICANT~~Dr. ~~ACCOUNTING~~Barath ~~POLICIES~~is an experienced Otorhinolaryngologist, who has worked for the last 14 years as an ENT performing head & neck surgeries. He graduated and obtained his MBBS degree from JSS Medical College, Sri Shivarathreeshwara Nagar, Mysore in 2009, and then obtained his postgraduate MS degree from Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Adgaon, Nashik in 2017. Since 2017, Dr. Bharath has been practicing at Pristyn Care Clinics in Bangalore. Pristyn Care is a health care startup that focuses on day care procedures. We believe that Dr. Bharath possesses attributes that qualify him to serve as a member of the Board, including his leadership skills, and experience.

~~This summary~~27 ofTable ~~significant accounting policies is presented to assist in understanding these financial statements. The financial statements and notes are representations~~ of ~~management, who is responsible for their integrity and objectivity.~~Contents

~~Use~~ Dr. Shrutin Ashok Ulman - Dr. Ulman is a qualified senior professional with 30 years’ experience in life sciences/medical devices including end-to-end product development and management, value proposition development in diagnostics and therapeutics. Seeking challenging senior managerial assignments with a reputed organization to utilize acquired skills in accomplishing organizational growth objectives. Specifically, since 2019, Dr. Ulman has been acting as a director Philips, India where his work includes defining and setting up strategic partnerships and interacting with the stakeholders to align product deliverables to the business requirements of ~~Estimates~~the clients, spearheading and collaborating with multiple teams for piloting clinical trials and clinical studies, focusing on R&D innovation, and rolling out new product development strategies, and working on digital therapeutics. Additionally, he is currently the Head Researcher of Africa Philips, Nairobi, working to ensure access to care, sustainability, and risk management of value/supply chains catering to areas like Digital Primary Care Solutions and Digital Therapeutics. We believe that Dr. Ulman possesses attributes that qualify him to serve as a member of the Board, including his leadership skills, and experience.

~~The preparation~~Significant ~~of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures~~Employees. ~~Accordingly, actual results could differ from those estimates.~~

~~Cash~~None.

~~The Company~~Family ~~considers all cash balances on deposit with financial institutions and highly liquid investments with a maturity of three months or less to be cash equivalents~~Relationships.

~~Property and Equipment~~None.

~~Property and~~Involvement ~~equipment~~in isCertain ~~stated~~Legal ~~at cost less accumulated depreciation~~Proceedings. ~~Depreciation is computed using the straight-line method over estimated useful lives listed below:~~

~~Estimated~~No ~~Useful~~officer, ~~Life~~director, ~~Building~~or 15persons nominated for such positions, promoter or significant employee has been involved in the last ten years in any of the following:

~~F-6~~· Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; · Any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); · Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; and · Being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.

~~Income Taxes~~Code of Ethics.

~~We account~~The ~~for~~Company ~~income~~has ~~taxes~~not ~~under~~yet ~~the~~formally ~~asset~~adopted ~~and~~a ~~liability~~Code ~~method,~~of ~~which~~Ethics ~~requires~~due ~~the~~to ~~recognition~~its ofcurrent ~~deferred~~size ~~tax assets~~ and ~~liabilities for~~limited ~~the~~number ~~expected future tax consequences~~ of ~~events~~employees. ~~that~~Management ~~have~~and ~~been included in~~ the ~~financial~~Board ~~statements.~~of ~~Under~~Directors ~~this~~intend ~~method,~~to ~~we determine~~adopt ~~deferred tax assets~~ and ~~liabilities~~implement ona ~~the~~Code ~~basis~~ of ~~the~~Ethics ~~differences~~consistent ~~between~~with the ~~financial~~requirements ~~statement~~of ~~and~~Item ~~tax~~406 ~~bases~~ of ~~the~~ ~~asset~~Regulation ~~and~~S-K ~~liabilities~~during ~~by using enacted tax rates in effect for~~ the fiscal year inending ~~which~~July ~~the~~31, ~~differences are expected to reverse~~2026. ~~The~~ ~~effect~~Until offormal aadoption, ~~change~~the inCompany’s ~~tax~~management ~~rates~~and ondirectors ~~deferred~~have ~~tax~~committed ~~assets~~to ~~and~~conduct ~~liabilities~~all isbusiness ~~recognized~~ in ~~income~~accordance inwith the ~~period~~principles ~~that~~of ~~includes the~~honesty, ~~enactment~~integrity, ~~date~~and accountability described above.

~~We recognize~~Audit deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. We provided 100% allowance to the deferred tax asset and was directly written-off to other expenses.Committee

~~We record~~Our ~~uncertain~~Board ~~tax~~of ~~positions~~Directors incurrently ~~accordance~~serves ~~with~~as ~~ASC 740 on~~ the ~~basis~~Audit ofCommittee, aand ~~two-step~~the ~~process~~Company indoes ~~which (1) we determine whether it is more likely than~~ not ~~that~~have ~~the~~a ~~tax~~separately ~~positions~~designated ~~will~~standing beaudit ~~sustained~~committee. onGiven the ~~basis~~Company’s ofsmall ~~the~~size, ~~technical~~limited ~~merits~~operations, ~~of the position~~ and ~~(2) for~~financial ~~those~~resources, ~~tax positions that meet~~ the ~~more-likely-than-not~~Board ~~recognition~~has ~~threshold.~~determined Wethat ~~recognize~~ the ~~largest~~establishment ~~amount~~ of ~~tax~~a ~~benefit that~~separate isaudit ~~more~~committee ~~than~~is 50not ~~percent~~yet ~~likely to be realized upon ultimate settlement with the related tax authority~~practical.

~~Revenue Recognition~~28 Table of Contents

The ~~Company~~ ~~recognizes~~functions ~~revenues~~customarily ~~and~~assigned ~~the~~to ~~related costs when persuasive evidence of~~ an ~~arrangement~~audit ~~exists~~committee, ~~delivery~~including ~~and~~oversight ~~acceptance has occurred, the price is fixed or determinable, and collection~~ of any resulting receivable is reasonably assured. Costs and expenses are recognized during the period in which they are incurred. Any revenues earned are from the sales of office equipment. The Company recognizes these sales once delivery time is confirmed by the customer.:

~~All revenue~~· ~~generated~~the byintegrity ~~the~~of ~~Company~~our tofinancial ~~date~~statements, ~~has~~· ~~been~~our ~~generated~~compliance ~~from~~with ~~U.S.~~legal ~~sales~~and regulatory requirements, · the qualifications, independence, and ~~deposited~~performance toof our ~~U.S.~~independent ~~bank~~registered ~~account~~public accounting firm, and · our internal controls over financial reporting, are performed by the full Board of Directors.

FThe Board of Directors has determined that none of its current members meets the definition of an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-7K. At this time, the Company lacks the financial resources to retain such an individual. The Board intends to appoint at least one director who qualifies as an audit committee financial expert as the Company’s financial position and staffing permit.

~~Recent Accounting~~All ~~Pronouncements~~audit and non-audit services performed by our independent registered public accounting firm are approved in advance by the Board of Directors acting in its capacity as the audit committee.

~~Management has~~ITEM ~~considered all recent accounting pronouncements issued since the last audit of our financial statements~~11. ~~The~~EXECUTIVE ~~Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements~~COMPENSATION.

~~NOTE 3~~For the fiscal years ended July 31, 2025, 2024, and 2023, we compensated our three highest-paid ~~GOING~~directors ~~CONCERN~~and executive officers as follows:

The accompanying financial statements and notes have been prepared assuming that the Company will continue as a going concern.

Name and principal position

Year

Ended

Salary

Bonus

Stock

Compensation

Option

Awards

Non-Equity

Incentive

Plan

Compensation

Nonqualified

Deferred

Compensation

Earnings

All Other

Compensation

Total

($)

Naveen Krishnarao Kulkarni, (1)

2025

90,000

–

Chief Executive

2024

90,000

–

Officer, President, Secretary, Treasurer, Director

2023

52,500

–

300

–

Manu Bharath Khareedhi, Director (2)

2025

–

2024

–

2023

–

Shrutin Ashok Ulman, Director (3)

2025

–

2024

–

2023

–

~~For~~ (1) On May 23, 2023, the ~~year~~Company ~~ended~~entered ~~July~~into 31an Executive Employment Agreement with Mr. Kulkarni whereby Mr. Kulkarni agreed to serve as the Company’s Chief Executive Officer, ~~2018~~President, Chief Financial Officer, Treasurer, Secretary, and as Chairman of the Company’s ~~had~~Board aof ~~net~~Directors. ~~loss~~The Employment Agreement became effective as of ~~$28~~June 1,~~167~~ 2023, (the “Effective Date”) and anhad ~~accumulated~~a ~~deficit~~term ofthat ~~$54~~expires on May 31,~~824~~ 2024. The Company~~’s ability~~ toand ~~continue~~Mr. asKulkarni ahave ~~going~~extended ~~concern~~the isterm ~~dependent~~of ~~upon~~the Executive Employment Agreement by mutual agreement. Under the terms of the Employment Agreement, the Company’s ~~ability~~shall tocompensate ~~generate~~Mr. ~~sufficient~~Kulkarni: ~~revenues~~(i) toa ~~operate profitably~~base orsalary ~~raise~~of ~~additional~~$90,000 ~~capital~~per ~~through~~year, ~~debt~~payable ~~financing~~at a rate of $7,500 per month during, which accrues and~~/or~~ ~~through~~any ~~sales~~outstanding balance becomes due and payable as soon as reasonably practicable; (ii) issue 29,500,000 restricted shares of the Company’s common stock valued at $0.001 per share; and, (iii) issue 500,000 restricted shares of the Company’s Series B Preferred Stock valued at $0.001 per share.

~~Management plans~~(2) toOn ~~fund~~June ~~operations~~7, of2023, ~~the~~Manu ~~Company~~Bharath ~~through~~Khareedhi ~~the~~was ~~proceeds~~appointed ~~from an offering pursuant~~ to athe ~~Registration~~Company’s ~~Statement~~board onof ~~Form~~directors ~~S-1 or~~as ~~private~~an ~~placements~~independent ofdirector. ~~restricted~~Mr. ~~securities~~Bharath ordid ~~the~~not ~~issuance~~receive ofany ~~stock~~compensation in ~~lieu~~2023 ofand ~~cash~~will ~~for~~be ~~payment~~compensated of$1,500 ~~services~~per ~~until~~every ~~such~~in-person ameeting ~~time as~~of ~~profitable~~the ~~operations~~board ~~are~~of ~~achieved~~directors.

~~There are~~(3) noOn ~~written~~June ~~agreements~~7, in2023, ~~place~~Shrutin ~~for~~Ashok ~~such~~Ulman ~~funding~~was orappointed ~~issuance~~to ofthe ~~securities~~Company’s ~~and~~board ~~there~~of ~~can~~directors beas noan ~~assurance~~independent ~~that~~director. ~~such~~Mr. ~~will~~Ulman ~~be available~~did innot ~~the~~receive ~~future.~~any ~~Management~~compensation ~~believes~~in ~~that~~2023 ~~this~~and ~~plan~~will ~~provides~~be ancompensated ~~opportunity~~$1,500 ~~for~~per ~~the~~every ~~Company~~in-person tomeeting ~~continue~~of asthe aboard ~~going~~of ~~concern~~directors.

~~The failure~~Other tothan ~~achieve~~the forgoing, no officer or director has received any compensation from the ~~necessary~~Company ~~levels~~since the inception of ~~profitability~~the orCompany. ~~obtain~~Until the Company acquires additional ~~funding~~capital, ~~would~~it beis ~~detrimental~~not toanticipated that any officer or director will receive compensation from the Company other than reimbursement for out-of-pocket expenses incurred on behalf of the Company.

~~NOTE 4~~The Company has no stock option, retirement, pension, or profit-sharing ~~PROPERTY~~programs ~~AND~~for ~~EQUIPMENT~~the benefit of directors, officers, or other employees, but our sole officer and director may recommend adoption of one or more such programs in the future.

~~Property and~~There ~~equipment~~are ~~consist~~no understandings or agreements regarding compensation our management will receive after a business combination that is required to be disclosed. The Company does not have a standing compensation committee or a committee performing similar functions, since the Board of Directors has determined not to compensate the ~~following:~~officer and director until such time that the Company completes a reverse merger or business combination.

	2018		2017
Building	$	-	$	11,900
Less accumulated depreciation		-		(1,305	)
	$	-	$	10,595

Table of Contents

~~F-8~~CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

~~The Company’s~~ITEM ~~former principal offices were located at 3 Rabi, Rabi, Czech Republic, 34201~~12. ~~The~~SECURITY ~~property~~OWNERSHIP ~~was~~OF ~~purchased~~CERTAIN onBENEFICIAL ~~July 30,~~OWNERS ~~2015~~AND ~~for~~MANAGEMENT ~~$11,900.~~AND ~~The~~RELATED ~~building~~STOCKHOLDER ~~was impaired and taken as a loss on May 14, 2018 as result of change in control~~MATTERS.

~~Depreciation expense~~Transactions ~~for~~with ~~the~~Related ~~years ended July 31, 2018 and 2017 was $435 and $580, respectively.~~Persons

~~NOTE 5~~On February 21, 2023, Reliant Service Inc., a Nevada corporation (the “Company”) entered into that certain Asset Purchase Agreement (“Purchase Agreement”), between the Company and Quantumzyme Inc., a Delaware corporation, (“Quantumzyme”) and Mr. Naveen Krishna Rao Kulkarni, an individual (“Mr. Kulkarni”), the sole officer, director, and shareholder of Quantumzyme (collectively, Quantumzyme and Mr. Kulkarni are hereinafter referred to as the “Seller”) pursuant to which the Company acquired various assets from the Seller, such assets are applied to and used in the “Enzyme Catalyst” biotransformation sector. Specifically, the assets acquired focus on clean and green chemistry used to enhance enzyme activity, selectivity, and specificity by applying novel quantum mechanics, molecular modelling, and engineering approaches. The “Enzyme Catalyst” is aimed at converting legacy chemical reaction into green chemistry (collectively, the Enzyme Catalyst, all related proprietary and nonproprietary technology, know-how, ~~COMMON~~and ~~STOCK~~all ~~AND~~other ~~ISSUANCE~~facets of Seller’s assets are referred to hereinafter as the “Acquired Assets”). In exchange for the Acquired Assets, the Company issued Mr. Kulkarni One Hundred Fifty Million (1,500,000) restricted shares of the Company’s common stock, representing approximately Seventy-Three (73%) percent of the Company’s issued and outstanding shares.

~~On July~~Policies ~~17,~~and ~~2015,~~Procedures ~~4,000,000 shares were issued to our sole director~~ for ~~$4,000.~~Related-Party Transactions

~~On October~~Our ~~28,~~Company ~~2016,~~does ~~pursuant~~not tohave ~~the~~any ~~company’s~~formal ~~Registration~~written ~~Statement~~policies onor ~~Form~~procedures ~~S-1~~for related party transactions, 1however in practice,~~015,000~~ ~~shares~~our ~~were~~Board ~~issued~~of Directors reviews and approves all related party transactions and other matters pertaining to 31the ~~independent shareholders.~~integrity ~~The~~of ~~shares~~management, ~~were~~including ~~issued~~potential atconflicts aof ~~per~~interest ~~share~~and ~~price~~adherence to standards of $0business conduct.04 ~~for~~We ~~total~~have ~~proceeds~~two independent directors on our Board of ~~$40,600~~Directors.

~~The Company~~Changes ~~has~~in ~~authorized 75,000,000 common shares at $0.001 par value, of which 5,015,000 shares were issued and outstanding as of July 31, 2018.~~Control

~~NOTE 6~~There -are ~~DEBT~~no present arrangements or pledges of the Company’s securities, which may result in a change in control of the Company.

~~On July~~The ~~10,~~Board ~~2018, the current director and president~~ of ~~the~~Directors ~~Company~~is ~~paid~~currently oncomposed ~~behalf~~ of ~~the~~four ~~company~~member ~~certain expenses during the transition period of changing control. The current director waived such payables due to him~~ and ~~the~~we ~~Company~~have ~~recorded~~two ~~such~~independent ~~waiver~~directors asat anthis ~~addition to additional paid in capital~~time.

~~NOTE 7~~ITEM -14. ~~RELATED~~PRINCIPAL ~~PARTY~~ACCOUNTANT ~~TRANSACTIONS~~FEES AND SERVICES.

~~On April~~Audit 14, 2015 the Director and President of the Company made the initial deposit to the Company bank account in the amount $100. The loan is non-interest bearing, unsecured and due upon demand. The loan was assumed by the former shareholder on May 14, 2018 as result of change in control. The assumption is taken as an addition to additional paid in capital.Fees

~~F-9~~The aggregate fees incurred by the Company’s principal accountant for the audit of the Company’s annual financial statements, review of financial statements included in the quarterly reports and other fees that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the years ended July 31, 2025 and 2024 were $19,668 and $10,000, respectively, all of which was paid to FRUCI & ASSOCIATES II, PLLC.

~~On July~~Audit ~~17,~~Related 2015, 4,000,000 shares of the Company’s common stock were issued to our sole director for $4,000. The Company’s sole officer and director is involved in other business activities and may in the future, become involved in other business opportunities as they become available.Fees

~~On July~~The ~~10,~~aggregate ~~2018,~~fees billed for professional services that are reasonably related to the ~~current~~performance ~~director~~of ~~and~~the ~~president~~audit or review of the Company’s ~~paid~~financial onstatements ~~behalf~~but ofare not reported “Audit Fees” for the ~~company~~years ~~certain~~ended ~~expenses~~July ~~during~~31, 2025 and 2024 in the ~~transition period~~amounts of ~~changing~~$0 ~~control~~and $0, respectively. ~~The~~All ~~current~~services ~~director~~performed ~~waived~~by ~~such~~the ~~payables~~Company’s ~~due~~Registered toPublic ~~him~~Accounting ~~and~~Firm, ~~the~~FRUCI ~~Company~~& ~~recorded~~ASSOCIATES ~~such~~II, ~~waiver~~PLLC. ashave anbeen ~~addition to~~pre-approved ~~additional~~by ~~paid~~the inCompany’s ~~capital~~Board of Directors.

~~NOTE 8~~Tax -and ~~FAIR~~All ~~VALUE~~Other ~~MEASUREMENTS AND DISCLOSURE~~Related Fees

~~FASB ASC~~Other ~~820~~fees ~~defines~~billed ~~fair value, establishes a framework~~ for ~~measuring~~products ~~fair value, and establishes a hierarchy of fair value inputs. Fair value is the price that would be received to sell an asset~~ or ~~paid~~services toprovided ~~transfer~~by ~~a liability in an orderly transaction between market participants at~~ the ~~measurement~~Company’s ~~date. A fair value liability occurs in the~~ principal ~~market~~accountant ~~for~~during the ~~asset~~years orended ~~liability or,~~July ~~in the absence of a principal market~~31, ~~the~~2025 ~~most~~and ~~advantageous market~~2024. ~~Valuation~~There ~~techniques~~were ~~that~~no ~~are~~fees ~~consistent~~incurred ~~with~~to ~~the~~FRUCI ~~market, income~~& orASSOCIATES ~~cost approach~~II, ~~as specified by FASB ASC 820~~PLLC, ~~are~~PS. ~~used~~Inc. related to ~~measure~~all ~~fair~~other ~~value~~fees.

~~The fair~~30 ~~value~~Table ~~hierarchy~~of ~~prioritized the inputs to valuation techniques used to measure fair value into three broad levels:~~Contents

~~Level I~~PART ~~inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities the Company has the ability to access.~~IV

~~Level II~~ITEM ~~inputs~~15. ~~are~~EXHIBITS ~~inputs~~AND ~~other~~FINANCIAL ~~than~~STATEMENT ~~quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly~~SCHEDULES.

~~Level III~~(a) ~~are~~Documents ~~unobservable~~filed ~~inputs~~as ~~for~~part ~~the~~of ~~asset~~this ~~or liability and rely on management’s own assumptions that market participants would use in pricing the asset or liability~~Report. ~~The unobservable inputs should be developed based on the best information available in the circumstances and may include the Company’s own data.~~

As 1. Financial Statements. The Company’s Balance Sheets as of July 31, ~~2018~~2025 and ~~2017~~2024, ~~there~~the ~~were~~Statements noof ~~level~~Operations Ifor the years ended May 31, II2025 and 2024, orthe ~~III~~Statements ~~assets~~of orChanges ~~liabilities~~in Stockholders’ Equity for the years ended July 31, 2025 and 2024, and the Statements of Cash Flows for the years ended July 31, 2025 and 2024, together with the notes thereto and the reports of FRUCI & ASSOCIATES, PS, as required by Item 8 are included in this 2025 Annual Report on Form 10-K as set forth in Item 8 above.

~~NOTE 9~~2. -Financial ~~SUBSEQUENT~~Statement ~~EVENTS~~Schedules. All financial statement schedules have been omitted since they are either not required or not applicable, or because the information required is included in the financial statements or the notes thereto.

~~In preparing~~3. ~~these~~Exhibits. ~~financial~~The ~~statements,~~following ~~the~~exhibits ~~company~~are ~~has~~either ~~evaluated~~filed ~~events~~as ~~and~~a ~~transactions~~part ~~for~~hereof ~~potential~~or ~~recognition~~are orincorporated ~~disclosure through~~by ~~November~~reference. ~~20,~~Exhibit ~~2018,~~numbers ~~the~~correspond ~~date~~to the ~~financial~~numbering ~~statements~~system ~~were~~in ~~issued.~~Item ~~There~~601 ~~are~~of noRegulation ~~subsequent events to be reported~~S-K.

F(b) Exhibits: We have filed the follow documents as exhibits required by Item 601 of Regulation S-10K (§229.601 of this chapter).

Number Description of Exhibit

3.1	Articles of Incorporation, as amended*
3.2	Amended Certificate of Designation filed February 20, 2024, with the Nevada Secretary of State**
3.3	Bylaws*
31.1	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rule 13A-14(A) Under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***
32.1	Certification pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. ***
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Schema
101.CAL*	Inline XBRL Taxonomy Calculation Linkbase
101.DEF*	Inline XBRL Taxonomy Definition Linkbase
101.LAB*	Inline XBRL Taxonomy Label Linkbase
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

	*	Previously Filed as part of the Company’s Registration Statement on Form 1-A, specifically as exhibits to the Part II-Offering Circular thereto, originally filed with the SEC on February 29, 2024.
	**	Previously Filed as part of the Company’s Registration Statement on Form 10 filed with the SEC on February 3, 2025.
	***	Filed herewith

	#	* Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Quantumzyme Corp.

Date: November 13, 2025	By:	/s/ Naveen Krishnarao Kulkarni
	Name:	Naveen Krishnarao Kulkarni
	Title:	Chief Executive Officer & Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Date: November 13, 2025	By:	/s/ Naveen Krishnarao Kulkarni
	Name:	Naveen Krishnarao Kulkarni
	Title:	Chief Executive Officer & Chief Financial Officer

Table of Contents

QUANTUMZYME CORP.

Index to Financial Statements

		Pages

Report of Independent Registered Public Accounting Firm (PCAOB ID 5525)		F-1

Financial Statements:

Balance Sheets as of July 31, 2025 and 2024		F-2

Statements of Operations for the years ended July 31, 2025 and 2024		F-3

Statement of Changes in Stockholders’ Deficit for the years ended July 31, 2025 and 2024		F-4

Statements of Cash Flow for the years ended July 31, 2025 and 2024		F-5

Notes to Financial Statements		F-6

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of Quantumzyme Corp.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Quantumzyme Corp. (“the Company”) as of July 31, 2025 and 2024, and the related balance sheets, statement of operations, stockholders’ deficit, and cash flows for each of the years in the two-year period ended July 31, 2025 and 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of July 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two-year period ended July 31, 2025 and 2024, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has an accumulated deficit, net losses, and negative cash flows from operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

Fruci & Associates II, PLLC – PCAOB ID #05525

We have served as the Company’s auditor since 2024.

Spokane, Washington

November 13, 2025

F-1

Table of Contents

QUANTUMZYME CORP.

(FORMALLY RELIANT SERVICES, INC.)

BALANCE SHEETS

ASSETS	July 31, 2025			July 31, 2024

Cash	$	584		$	-
Prepaid expenses		-			10,000
Total current assets		584			10,000

Total assets		584			10,000

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued expenses	$	175,218		$	109,780
Due to related parties		17,002			15,852
Notes payable		249,081			167,666
Total current liabilities		441,301			293,298

Total liabilities		441,301			293,298

Commitments and Contingencies (See note 7)		-			-

Preferred Shares 130,000,000 authorized shares, par value $0.00001
0 shares issued and outstanding as of July 31, 2025 and 2024, respectively		-			-
Series A Preferred Shares 10,000,000 authorized shares, par value $0.00001
0 shares issued and outstanding as of July 31, 2025 and 2024, respectively		-			-
Series B Preferred Shares 10,000,000 authorized shares, par value $0.00001
500 shares issued and outstanding as of July 31, 2025 and 2024, respectively		5			5
Common Shares 750,000,000 authorized shares, par value $0.00001; 38,962,050 and 34,777,050 shares issued and outstanding as of July 31, 2025 and 2024 , respectively		389			347
Additional paid-in capital		5,195,456			5,153,648
Accumulated deficit		(5,636,567	)		(5,437,298	)
Total stockholders' deficit		(440,717	)		(283,298	)

Total liabilities and stockholders' deficit		584			10,000

The accompanying notes are an integral part of these audited financial statements.

F-2

Table of Contents

QUANTUMZYME CORP.

(FORMALLY RELIANT SERVICES, INC.)

STATEMENTS OF OPERATIONS

	For the year ended
	July 31
	2025			2024

Sales	$	-		$	-

Operating expenses
General and administrative		18,129			31,727
Professional fees		162,408			131,866
Total operating expenses		180,537			163,593

Loss from operations		(180,537	)		(163,593	)

Other expense
Gain on extinguishment of debt		2,500			-
Interest expense		(21,232	)		(14,976	)
Total other expenses		(18,732	)		(14,976	)

Net loss before tax provision		(199,269	)		(178,569	)
Tax provision		-			-
Net loss	$	(199,269	)	$	(178,569	)

Net loss per common share: basic and diluted	$	(0.01	)	$	(0.01	)
Weighted average common shares outstanding - basic and diluted		35,117,811			34,742,014

The accompanying notes are an integral part of these audited financial statements.

No assurance provided

F-3

Table of Contents

QUANTUMZYME CORP.

(FORMALLY RELIANT SERVICES, INC.)

STATEMENT OF STOCKHOLDERS' DEFICIT

	Series B
	Preferred		Par		Common		Par		Paid-In		Stock			Accumulated			Stockholders'
	Shares		Value		Shares		Value		Capital		Payable			Deficit			Deficit
Balance, July 31, 2023		500		5		31,577,050		315		5,150,480		3,200			(5,258,729	)		(104,729	)
Share to be issued for settlement of notes payable						3,200,000		32		3,168		(3,200	)		-			-
Net loss															(178,569	)		(178,569	)
Balance, July 31, 2024		500		5		34,777,050		347		5,153,648		-			(5,437,298	)		(283,298	)
Shares issued for cash		-		-		4,185,000		42		41,808		-			-			41,850
Net loss		-		-		-		-		-		-			(199,269	)		(199,269	)
Balance, July 31, 2025		500		5		38,962,050		389		5,195,456		-			(5,636,567	)		(440,717	)

The accompanying notes are an integral part of these audited financial statements.

No assurance provided

F-4

Table of Contents

QUANTUMZYME CORP.

(FORMALLY RELIANT SERVICES, INC.)

STATEMENTS OF CASHFLOWS

	For the year ended
	July 31, 2025			July 31, 2024
Cash Flows from Operating Activities
Net loss	$	(199,269	)	$	(178,569	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Gain on extinguishment of debt		(2,500	)
Changes in assets and liabilities
Prepaid expenses		10,000			(10,000	)
Accounts payable		65,438			80,992
Due to related party		1,150			5,940
Net cash from operating activities		(125,181	)		(101,637	)

Cash Flows from Financing Activities
Proceeds from the issuance of common stock		41,850			-
Proceeds from notes payable		83,915			101,637
Net cash from financing activities		125,765			101,637


Net decrease in cash		584			-
Cash, beginning of period		-			-
Cash, end of period	$	584		$	-

Supplemental disclosure of cash flow information
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Share to be issued for settlement of notes payable	$	-		$	3,200

The accompanying notes are an integral part of these audited financial statements.

No assurance provided

F-5

Table of Contents

QUANTUMZYME CORP

(FORMALLY RELIANT SERVICES, INC.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

July 31, 2025 and 2024

NOTE 1 – NATURE OF BUSINESS AND OPERATIONS

Organization

Quantumzyme Corp. (formally Reliant Service Inc.) (the “Company”) was incorporated in the state of Nevada on March 20, 2015. The company develops marketing channels to distribute office equipment to the wholesale market in the United States. Our functional currency is the US Dollar and all the references to currency in the financial statements are in US Dollars.

On February 8, 2023, Ms. Sandra (Demeria) Brossart (“Brossart”) resigned as the sole-officer and director of the Company, and Mr. Naveen Krishna Rao Kulkarni (“Kulkarni”) was appointed as sole-officer and director in her place. Thereafter, on February 21, 2023, the Company entered into that certain Asset Purchase Agreement (“Purchase Agreement”), between the Company and Quantumzyme Inc., a Delaware corporation, (“Quantumzyme”) and Kulkarni, the sole- officer, director, and shareholder of Quantumzyme (collectively, Quantumzyme and Mr. Kulkarni are hereinafter referred to as the “Seller”) pursuant to which the Company acquired various assets from the Seller, such assets are applied to and used in the “Enzyme Catalyst” biotransformation sector. In exchange for the Acquired Assets, the Company issued Mr. Kulkarni One Hundred Fifty Million (1,500,000) restricted shares of the Company’s common stock (Post split), representing approximately Seventy-Three (73%) percent of the Company’s issued and outstanding shares.

On March 31, 2023, the Company changed its name to Quantumzyme Corp.

NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared in US dollars and in accordance with accounting principles generally accepted in the United States (“GAAP”) on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During the year ended July 31, 2025, the Company incurred net losses of $199,269, accumulated deficits of $5,636,567, and used cash in operations in the amount of $125,181. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

We are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner. We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all. The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations. Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock. If we are unable to obtain necessary financing, we will likely be required to curtail our development plans. Any additional equity financing may involve substantial dilution to our then existing stockholders.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

F-6

Table of Contents

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

Stock-based compensation

The Company follows ASC 718-10, “Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 is a revision to SFAS No. 123, “Accounting for Stock-Based Compensation,” and supersedes Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees,” and its related implementation guidance. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

Concentration of Credit Risk

The Company has no off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains all of its cash balances with two financial institutions in the form of demand deposits.

Loss per Share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

Revenue Recognition

The Company recognizes revenue from its contracts with customers in accordance with ASC 606 – Revenue from Contracts with Customers. The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.

Revenue related to contracts with customers is evaluated utilizing the following steps: (i) Identify the contract, or contracts, with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; (v) Recognize revenue when the Company satisfies a performance obligation.

Income Taxes

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

F-7

Table of Contents

Fair Value of Financial Instruments

The Company measures fair value in accordance with ASC 820 - Fair Value Measurements. ASC 820 defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurements. ASC 820 establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by ASC 820 are:

Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 - Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 - Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

As defined by ASC 820, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale, which was further clarified as the price that would be received to sell an asset or paid to transfer a liability (“an exit price”) in an orderly transaction between market participants at the measurement date

The reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of factors and assumptions. Accordingly, certain fair values may not represent actual values of the Company’s financial instruments that could have been realized as of July 31, 2025 and 2024 or that will be recognized in the future, and do not include expenses that could be incurred in an actual settlement. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, receivables from related parties, prepaid expenses and other, accounts payable, accrued liabilities, and related party and third party notes payables approximate fair value due to their relatively short maturities. The Company’s notes payable approximates the fair value of such instrument based upon management’s best estimate of terms that would be available to the Company for similar financial arrangements at July 31, 2025 and 2024.

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company adopted the ASU and determined that its adoption did not have a material impact on the Company’s consolidated financial statements and related disclosures. As defined in the ASU, operating segments are components of an enterprise about which discrete financial information is regularly provided to the CODM in making decisions on how to allocate resources and assess performance for the organization. The Company operates and manages its business as one reportable and operating segment. The Company’s CODM is the Chief Executive Officer. The Company’s CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company.

F-8

Table of Contents

The Company does not believe that other standards, which have been issued but are not yet effective, will have a significant impact on its financial statements.

NOTE 4 –PROMISSORY NOTES

Promissory notes payable as of July 31, 2025 and 2024 consists of the following:

	July 31, 2025		July 31, 2024
Dated June 14, 2021	$	6,000	$	6,000
Dated July 20, 2021		642		642
Dated February 10, 2023		15,300		15,300
Dated February 10, 2023		12,750		12,750
Dated March 14, 2023		6,161		6,161
Dated April 28, 2023		7,803		7,803
Dated April 28, 2023		8,077		8,077
Dated May 4, 2023		5,904		5,904
Dated July 31, 2023		3,392		3,392
Dated September 8, 2023		2,000		2,000
Dated September 11, 2023		2,500		2,500
Dated September 13, 2023		6,000		6,000
Dated September 20, 2023		2,000		2,000
Dated September 29, 2023		20,000		20,000
Dated October 11, 2023		25,000		25,000
Dated October 16, 2023		6,000		6,000
January 31, 2024		1,420		1,420
February 8, 2024		7,500		7,500
February 21, 2024		7,000		7,000
February 22, 2024		1,865		1,865
April 2, 2024		1,902		1,902
April 22, 2024		5,000		5,000
May 5, 2024		450		450
June 17, 2024		3,000		3,000
June 25, 2024		10,000		10,000
August 2, 2024		6,000		-
August 16, 2024		3,125		-
October 22, 2024		1,500		-
October 28, 2024		10,000		-
October 29, 2024		5,000		-
October 29, 2024		6,500		-
December 5, 2024		8,000		-
December 7, 2024		3,190		-
February 11, 2025		2,500		-
February 28, 2025		8,300		-
March 4, 2025		4,500		-
April 30, 2025		14,169		-
July 31, 2025		8,631		-
Total notes payable	$	249,081	$	167,666

F-9

Table of Contents

During the year ended July 31, 2025 and 2024, the Company issued various promissory notes amounting to $83,915 and $101,637 for general operating purposes to singe noteholder. The notes carry a 10% interest rate and are due upon 10 days written notice. As of July 31 2025 and 2024, the Company had amounts due to the note holder of $242,438 and $161,024, respectively.

On June 14, 2021, the Company issued a promissory note for proceeds of $6,000. The note is due on demand and accrues interest at 10% per annum. On July 17, 2023, the note holder sold and assigned $3,200 of the balance to two unrelated parties. On July 25, 2023, the new note holders settled the combined balance of $3,200 for the issue of 3,200,000 shares of common stock valued at $3,200.

On September 12, 2024, the Company issued two promissory notes for proceeds of $2,500. The notes carry a 10% interest rate and are due upon 10 days written notice. On November 30, 2024, the noteholders, forgave the balance of the notes for no consideration.

During the year ended July 31, 2025 and 2024, the Company recorded interest expense of $21,232 and 14,976, respectively.

NOTE 5 – RELATED PARTY TRANSACTIONS

As of July 31, 2025 and 2024, the amount due to related parties was $17,002 and $15,852, respectively. Amounts due to related parties are non-interest bearing and due on demand.

NOTE 6 – INCOME TAXES

The Company provides for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

The components of the Company’s deferred tax asset and reconciliation of income taxes computed at the statutory rate to the income tax amount recorded as of July 31, 2025 and 2024, are as follows:

	July 31,			July 31,
	2025			2024
Net operating loss carryforward	$	(5,636,567	)	$	(5,437,298	)
Statutory tax rate		21	%		21	%
Deferred tax asset		(1,183,679	)		(1,141,833	)
Less: Valuation allowance		1,183,679			1,141,833
Net deferred asset	$	-		$	-

As of July 31, 2025 and 2024, the Company had approximately $5.64 million and $5.44 million in net operating losses (“NOLs”), respectively that may be available to offset future taxable income. NOLs generated in tax years prior to July 31, 2019 can be carryforward for twenty years, whereas NOLs generated after July 31, 2019 can be carryforward indefinitely. In accordance with Section 382 of the U.S. Internal Revenue Code, the usage of the Company’s net operating loss carry forwards is subject to annual limitations following greater than 50% ownership changes.

F-10

Table of Contents

NOTE 7 - COMMITMENTS AND CONTINGENCIES

From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. Management is currently not aware of any such legal proceedings or claims that could have, individually or in the aggregate, a material adverse effect on our business, financial condition, or operating results.

NOTE 8 – STOCKHOLDERS’ EQUITY

The Company’s authorized common stock consists of 750,000,000 shares with par value of $0.00001. As of July 31, 2025 and 2024, the Company had 38,962,050 and 34,777,050 shares of common stock-issued and outstanding.

On February 21, 2023, the Company filed a Certificate of Amendment together with Amended & Restated Articles of Incorporation with the Secretary of State of the State of Nevada increasing the Company’s authorized shares of common stock from 75,000,000 to 900,000,000, consisting of 750,000,000 shares of Common Stock, par value $0.00001 and 150,000,000 shares of authorized but undesignated preferred stock, par value $0.00001.

On March 31, 2023, the Company’s Board of Directors approved a 1 to 100 reverse stock split as of the record date of March 31, 2023. As of the date of filing the reverse stock split has not been approved by FINRA. The financial statements have been retroactively restated to show the effect of the stock split.

On May 24, 2023, the Company filed a Certificate of Designation (“Certificate of Designation”) with the Secretary of State of the State of Nevada that provided for the creation of Series A Preferred Stock and Series B Preferred Stock from the previously authorized but undesignated shares of the Company’s preferred stock.

The Company’s Certificate of Designation designates 10,000,000 shares as Series A Preferred Shares the designations, powers, preferences, rights, and restrictions granted or imposed upon the Series A Preferred Shares and holders thereof are as follows:

	(i)	Series A Preferred Stock ranks senior to all other classes of stock;
	(ii)	(ii) Series A Preferred Stock is convertible at a ratio of 1:10; and,
	(iii)	(iii) Series A Preferred Stock votes by multiplying the number of shares of Series A Preferred Stock held by such holder by 100.

Additionally, the Company’s Certificate of Designation, designates 10,000,000 shares as Series B Preferred Shares the designations, powers, preferences, rights, and restrictions granted or imposed upon the Series B Preferred Shares and holders thereof are as follows:

	(i)	Series B Preferred Stock ranks junior to all other classes of Preferred Stock;
	(ii)	Series B Preferred Stock is convertible at a ratio of 1:50, and,
	(iii)	Series B Preferred Stock votes by multiplying the number of shares of Series B Preferred Stock held by such holder by 500.

During the year ended July 31, 2025, the Company issued 4,185,000 shares of common stock for $41,850 cash.

NOTE 9 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to July 31, 2025 to the date these financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

F-11

Filing Compare · Quantum Genesis AI Corp.